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Summary 
Non-coding RNAs can function as potent gene regulators and consequently, such RNA 
molecules have been implicated in many diseases including different types of cancer. 
Circular RNAs (circRNAs) are emerging as a new class of regulatory non-coding RNAs. 
Several studies have revealed that circRNAs are differentially expressed in several tissues 
and thus, some circRNAs were reported to play important roles in several diseases such 
as cancer, cardiovascular disease and neurological disease. 
Using an intrasplenic tumor model for colorectal cancer, we have identified several 
circRNAs differentially expressed in primary tumors and liver metastases suggesting a role 
of these RNAs in tumor progression. In this study, we have focused on characterization of 
circular RNA ZNF609 (circZNF609), which is up-regulated in primary tumors as well as 
liver metastases in our mouse model. We developed methods for knockdown and 
overexpression of circZNF609 and established several inducible stable cell lines for in vitro 
and in vivo analyses. Using two xenograft mouse models, we confirmed that circZNF609 
can function as oncogene to promote colorectal cancer progression.  
Interestingly, we found that circZNF609 encodes for small proteins, which could potentially 
have function in tumor development. Using Flag reporter constructs and mutagenesis, we 
identified several AUGs (even exogenous AUGs) which can be used to initiate translation 
from circZNF609. Moreover, circZNF609 protein localizes to the cytoplasm while the 
parental ZNF609 protein exclusively localizes to the nucleus. Mechanistically, mass 
spectrometry analysis identified several proteins of the integrator complex as interaction 
partners of both circZNF609 and ZNF609 proteins suggesting an interesting mode of 
circZNF609 functions. Further analysis of the molecular mechanisms of these interactions 
would shed lights on how circZNF609 functions.  
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1 Introduction 
1.1 Discovery of circRNAs  
CircRNAs are emerging as a new class of regulatory RNAs among several well-studied 
non-coding RNAs (ncRNAs) including small non-coding RNAs, long non-coding RNAs, or 
enhancer RNAs. Yet, circRNAs were discovered several years ago, first in the late 70s 
from plant viroids1,2 and then in the 80s from yeast mitochondrial RNAs3,4 intervening 
sequence of yeast ribosomal RNA precursor5,6,7 and hepatitis delta virus8. Subsequently, 
circRNAs were reported in mammalian cells as scrambled transcripts9,10 and considered 
as by-products of canonical splicing due to its low expression levels11. However, in some 
cases, circRNAs were found to be very abundant, such as Sry circRNA in mouse testis12 
or NCX1 circRNA13 and therefore suggested as functional products of canonical splicing12. 
Such circular events were more and more observed in the following years in several 
species and genes including the human and rat cytochrome 14,15,16; human dystrophin17, 
human and blood ETS-1 18 or rat, mouse, rabbit and monkey NCX1 13. Moreover, circular 
RNAs were successfully recapitulated in vitro using the ATC1 derived pre-mRNA transcript 
in yeast either from pseudocircular pre-mRNA19 or linear pre-mRNA20 and later on using 
the human -globin intron21 or PIP71 and PIP73 exons flanking by short intronic 
sequences22  in Hela cell extracts. These evidences confirm the existence of circRNAs but 
to identify those transcripts systematically was not possible at that time due to the lack 
suitable high-throughput technologies.  
An attempt to identify those circularized exons in 2012 in a high throughput manner led to 
the discovery of thousands of circRNA transcripts23. This is the first time, a systematic 
verification of circRNAs was confirmed showing that circRNAs are non-polyadenylated, 
predominantly cytoplasmic-localized and expressed at somehow similar level compared to 
their canonical linear isoforms in leukocytes. Subsequently, advance in next-generation 
RNA sequencing (RNA-Seq) of nonpolyadenylated or rRNA-depleted transcriptomes has 
recently updated the widespread expression of circRNAs in different organisms24,25,26, 
some of which have been biochemically confirmed to be highly expressed in a cell type-
specific or tissue-specific manner27,25,28,29. Bioinformaticians have developed various 
algorithms to detect genome-wide circRNA expression from RNA-Seq data in the past few 
years and a source of experimental and bioinformatic approaches has been addressed 
and discussed in several reviews30,31,32,33,34.  
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1.2 CircRNA properties 
CircRNAs are covalently closed single-stranded transcripts and resistant to the 
degradation by exonucleases, such as RNase R35,36. Since circRNAs do not contain a 5’ 
cap and a 3’ tail, they are very stable with half-lives much longer than observed for linear 
RNA counterparts37,28,38.  
Depending on how circRNAs are generated, 3 types of circRNAs are observed in cells 
across several species: exonic circRNAs, intronic circRNAs, and exon-intron circRNAs39 
(Fig. 1.1 A). Exonic circular RNAs are the most abundant and well-studied circRNAs40. 
These circRNAs are very conserved between different species and localized 
predominantly in the cytoplasm28,38. Intronic circRNAs were first discovered in the early 
80s, many of those came from intron lariats and resist to debranching enzymes41,42. Exon-
intron circRNAs, or EIciRNAs, come from back-splicing and are regulated by 
complementary sequence flanking its circularized exon-intron part43. In general, intron-
containing circRNAs localizes exclusively in the nucleus42,43.  
1.3 CircRNA biogenesis 
CircRNAs were initially considered as by‑products of aberrant splicing10,11. Recent studies 
about circRNA biogenesis have revealed that circRNAs are produced via back-splicing, a 
highly regulated process controlled by several cis and trans regulators44–50,51,52,53. In 
contrast to the canonical splicing, back-splicing joins a downstream splice donor site with 
an upstream splice acceptor site46 (Fig. 1.1 A). However, how the spliceosome and which 
factors of the spliceosome are involved in back-splicing is not clear54. Mutagenesis of 
splice sites and using splicing inhibitor isoginkgetin to block spliceosome assembly 
showed that canonical spliceosomal machinery is required for back-splicing53. Moreover, it 
was proposed that linear splicing and back-splicing may compete with each other, 
suggesting that both processes share some similar splicing activities45 while  recent 
research also showed that regulation of back-splicing has different rules and therefore 
requires different splicing factors55. Indeed, very recently, it was shown that circRNA 
expression increases while expression of their cognate linear mRNAs decreases when the 
core spliceosomal components are depleted56. Nevertheless, it is now clear that back-
splicing is promoted by regulatory elements residing in the flanking introns of the 
circularized exons44,51,52,49 and could be repressed or enhanced by RNA-binding proteins 
(RBPs)50,47,52,53,55,57,58,59,60. Still, it is not clear how back-splicing is linked to transcription. It 
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is still a matter of debate of whether circRNAs are produced co-transcriptionally48,51 or 
post-transcriptionally45,52. It was also reported that circular RNAs from downstream genes 
could be produced via readthrough transcription56 (Fig. 1.1 C).  
 CircRNA biogenesis regulated by cis elements 1.3.1
In the late 90s, circular RNAs were successfully recapitulated in vitro19–22 and many 
evidences implied that the complementary sequence of flanking intron for base pairing 
between 5’- and 3’-ends is required for circRNA production20,12,61. Genome-wide analysis 
to identify cis-sequence elements using sequences upstream or downstream from 
backsplice sites revealed the presence of Alu repeats in flanking introns, which are often 
very long28,49. Since Alu repeats are only presented in primates, analysis of circRNAs in 
other organisms is necessary to understand circRNA biogenesis mechanism. Analysis of 
introns from Caenorhabditis elegans indicated reverse complementary matches are 
important for circRNA biogenesis44. Therefore, reverse complementary sequence, 
including Alu elements, are now considered as a conserved feature of circRNA biogenesis 
since the pairing of those sequence to form RNA duplexes significantly enhances back-
splicing49,51,52. Indeed, those reverse complementary sequences have been validated 
experimentally and are becoming useful tools for circRNA overexpresion51,52 or circRNA 
knockout via CRISPR/Cas962. Interestingly, due to the availability of several reverse-
orientated Alu elements in one intron, competition of these elements for RNA pairing 
across intron can lead to the formation of different circRNAs. This process is called 
alternative circularization49. This event together with alternative splice site selection leads 
to diversity in the landscape of circRNAs63,64 (Fig. 1.1 B).  
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Fig. 1.1 Biogenesis of circRNAs A) Three types of circRNAs were detected and profiled from 
cells. Intronic circRNAs are generated from intron lariats and are resistant to debranching 
enzymes42. Exonic circRNAs are generated via back-splicing of one or several exons40. Exon-
intron circRNAs are circularized exons with part of retained flanking intron43. B) Alternative 
circularization mechanisms. Multiple circRNAs can be produced from a single gene locus with 
different numbers of exons included. This is regulated by the competition of RNA pairing across 
different introns49. C) CircRNAs can be regulated through transcription. For examples, in neurons, 
circRNAs are upregulated because of fast transcription and accumulation48. In some cases, 
production of circular RNAs from downstream genes can be generated through back-splicing of a 
readthrough transcripts produced from the promoter of upstream gene56. In other cases, circRNAs 
are upregulated when the core components of spliceosomes are depleted56.   
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 CircRNA biogenesis regulated by RBPs 1.3.2
Recent works indicated that back-splicing activities are not only driven by cis intron-pairing 
but can also be affected by trans-acting factors such as RBPs. In some cases, the 
production of circRNAs is controlled by several proteins acting in a combinatorial manner, 
for instance, the action of multiple heterogeneous nuclear ribonucleoprotein hnRNP and 
serine–arginine SR proteins52.  In other cases, the production of several circRNAs, for 
instance, 80 different circRNA isoforms of the titin gene, are regulated by a single protein 
as shown for the splicing factor RBM2060. Indeed, ADAR144,65 and DHX957 antagonize 
circRNA formation while QKI50, MBL/MBNL145, hnRNPs and SR protein52 and 
NF90/NF11047 promote circularization. Moreover, HNRNPL59 or FUS58 could either 
enhance or inhibit circRNA production (Fig. 1.2).  
Analysis of flanking introns of circRNAs also revealed that these sequences are enriched 
in adenosine to inosine (A-to-I) editing and therefore ADAR1 was proposed to binds to 
these pairing intron regions and converts adenosines to inosine44. This was experimentally 
confirmed by the fact that the production of a subset of circRNAs was upregulated when 
ADAR1 is depleted in different human and mouse cell lines65,44. Another study showed that 
DHX9, a nuclear RNA helicase, binds specifically to inverted-repeat Alu as well as 
interferon-inducible isoform of ADAR (p150) in an RNA-independent interaction manner. 
This indicates that DHX9 may antagonize circRNA formation. Indeed, loss of DHX9 leads 
to an increase of several circRNAs and co-depletion of ADAR and DHX9 enhances 
circular RNA production, suggesting a cooperative actions between these two enzymes in 
circRNA biogenesis57 (Fig. 1.2 A).  
A screen for splicing factors that regulate circRNA biogenesis using a dual color reporter 
construct, circScreen, showed that the production of several abundant circRNAs is 
regulated by QKI, an alternative splicing factor50. QKI binds to its consensus motif within 
introns flanking the circRNA-forming exon. Indeed, insertion of QKI motifs is sufficient to 
induce novel circRNA formation. Moreover, QKI knockdown or overexpression showed 
downregulation or upregulation of several circRNAs, therefore confirming its roles in 
regulating circRNA expression50 (Fig. 1.2 B).  
 
INTRODUCTION          17 
 
 
 
 
Fig. 1.2 Factors that regulate circRNA biogenesis. A) Exons of circRNAs are usually located in 
between very long introns28. These intron sequences contain Alu elements28 or reverse 
complementary sequence44 that forms RNA duplexes. The RNA pairing between the flanking 
introns facilitates circRNA production44,49. Some RBPs such ADAR or DHX9 bind to these RNA 
duplexes and break the pairing between these RNA duplexes44,57.  Some other RBPs such as 
NF90/NF110 bind and enhance RNA pairing between Alus, and therefore promote circRNA 
production47. B) Some RBPs binds to their own motifs in the flanking intron. The binding of these 
RBPs such as FUS58, QKI50 or MBNL145 enhances circRNA production. In other cases, the 
production of circRNAs could be positively or negatively regulated by splicing factor such as 
HNRNPL59 or spliceosomal components56.  
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Another attempt using genome-wide siRNA screening coupled to dual color reporter 
strategies identified several RBPs which could regulate circRNA biogenesis47. Specifically, 
the dsRNA-binding proteins NF90/NF110 bind RNA duplexes formed by inverted repeat 
elements in the introns flanking the circularized exon. Further analysis revealed that those 
inverted repeat elements are intronic Alu repeat and i-CLIP indicated that NF90 preferred 
to bind clusters of A-rich or U-rich sequences which are located to Alus in introns. This 
binding was shown to stabilize pairing introns for production of circRNAs (Fig. 1.2 B). 
Some circRNAs were shown to be downregulated upon NF90 depletion and the 
expression of those circRNAs was rescued when Flag-NF90, but not Flag-NF90 
truncations, is re-expressed in those knockdown cells47. Upon poly(I:C) treatment or VSV 
infection, it was suggested that NF90/110 translocate to the cytoplasm and therefore 
downregulate the expression of nascent circRNAs. In untreated cells, RIP experiments 
showed that NF90/110 binds to some circRNAs but these binding reduced upon 
treatment. Moreover, vsvm mRNAs compete with circDHX34, but not linear DHX34 
mRNA, for binding to NF90. This suggested a model that upon viral infection, the 
expression of circRNAs are downregulated due to translocation of NF90/NF110 to the 
cytoplasm, and there NF90/NF110 can bind to viral mRNAs for immune response47.  
Apart from binding to the Alu repeat sequence, several RBPs were shown to bind to its 
own motif in the introns juxtaposing the circRNA-forming exon, as shown from QKI. 
circRNA transcriptome profiling for FUS WT/KO cells58 or HNRNPL WT/KD cells59 
identified several up- or down-regulated circRNAs. Specifically, up-regulated circRNAs 
significantly associate with HNRNPL binding to its own motifs and down-regulated 
circRNAs to some extent changed upon HNRNPL knockdown. Interestingly, minigene 
constructs containing the HNRNPL binding site (CA)20 to both of the flanking introns 
significantly enhances circRNA formation59. Another study showed that FUS depletion and 
mutation affect circRNA expression and FUS interacts with its binding sites in pre-mRNA 
regions controlling biogenesis of a few specific circRNAs58 (Fig. 1.2 B). 
Another interesting example comes from the splicing factor Muscleblind (Mbl) Drosophila 
melanogaster or MBNL1 in human45. Mbl regulates circularization of its own exon 2 from 
its pre-mRNA by binding to the putative Mbl binding site in the flanking intron. This was 
further proven by using minigene containing Mbl binding sites in the circMbl flanking 
introns under Mbl overexpression (Fig. 1.2 B). Specifically, Mbl overexpression augments 
the production of circMbl or circTim flanked by Mbl introns45. Furthermore, circMbl was 
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shown to bind to its parental protein, Mbl, and control expression of its own expression. It 
was proposed that when the expression of Mbl protein is high, the expression of Mbl 
mRNA is decreased by enhancing the production of circMbl, which then sponges 
excessed MBL protein45.  
1.4 CircRNA functions 
 CircRNAs can function as miRNA sponges 1.4.1
The competiting endogenous RNA (ceRNAs) hypothesis proposes that specific RNAs can 
sequester miRNAs and impair miRNA activity and therefore upregulate mRNA target gene 
regulation66,67. circRNAs are presumably ideal candidates for miRNA sponges (Fig. 1.3 F) 
because they are more stable and they lack both 5’ and 3’ ends, which facilitate escaping 
from exonuclease and degradation68,69. Indeed, the circRNA CDR1as (or ciRS-7) contains 
more than 70 miR-7 seed sequences and associates with Ago2 without being 
degraded70,26. Interestingly, knockout of CDR1as in mice shows miR-7 deregulation and 
increases the expression of targets of miR-771. The second circRNA namely Sry contains 
16 binding sites for miR-138 and therefore is proposed to act as a sponge70. However, 
only CDR1as and Sry stood out as two exceptional cases because such multiple binding 
sites for miRNA in one specific transcript is usually not found in nature. In fact, a 
comprehensive analysis also pointed out that most circRNAs do not contain several 
miRNA binding sites, except a few circRNAs from the ZNF gene family69. Moreover, given 
that some circRNAs are lowly expressed, a change in expression of a circRNA would not 
be sufficient to titrate miRNA away from their target69. This finding is supported by earlier 
study using high-throughput assay called Sensor-seq for quantification the activity of 
hundreds of miRNAs. This work showed that only the most abundant miRNAs in a cell can 
mediate target suppression72. However, it was also showed that miRNA-target ratios 
determine the potential for ceRNA regulation73. Specifically, highly expressed miR-294 and 
let-7 families are unsusceptible to ceRNAs while active miR-25 family, which has lower 
miRNA:target ratios, may be more sensitive to ceRNA activities73. Since ceRNA 
hypothesis has been actively debated67, any experiments of circRNA-miRNA sponges 
should be carefully performed to get a convincing conclusion.  
Moreover, binding of miRNAs and Ago2 to a circRNA does not necessarily lead to miRNA 
suppression. For instance, ciRS-7 contains only one binding site for miR-671 and is 
cleaved by Ago2 in a RISC-dependent manner74,70. Therefore, binding of miRNAs and 
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Ago2 may have different functions than miRNA sponges. Depending on the sequence 
context of binding between circRNAs and miRNAs, the association of miRNA and Ago2 to 
circRNA might lead to circRNA degradation. Still, several studies suggested that miRNA 
sponges as a common feature of several circRNAs (Table 2).  
 CircRNAs can serve as temples for translation 1.4.2
circRNA translation is not new. Before the era of long non-coding RNAs, every circRNA 
found was asked for coding potential by recapitulating its ORF over circRNA junction. The 
first circRNA with coding potential was discovered in 1985 and came from an intron 
circRNA of archaebacterium Desulfurococcus mobilis75. This 622 bp circRNA is proposed 
to generate a protein of 194 aa with a putative Shine-Dagano sequence, GGGGU, that is 
complementary to 3’ end of 16S RNA76. This circRNA was then proved to encode for a 
protein called I-Dmo I which functions as an endonuclease77. Afterwards, 2 other intronic 
circRNAs from the hyperthermophilic archaeon Pyrobaculum organotrophum were also 
proposed to encode for proteins78. 
In mammals, the first circRNA was mentioned to have coding potential and its protein was 
suggested to be functional is from an abundant circRNA produced from NCX1 gene13. This 
is consistent with the observation that circRNA with internal ribosome entry sites (IRES) 
could be translated in vitro79. Notably, ribosome profiling, or Ribo-seq, is a powerful 
method for analyzing translation in vivo using next generation sequencing of ribosome-
protected mRNA fragments80,81. Therefore, this could be also applied for studying circRNA 
translation if its RNA fragments are protected by ribosomes. However, only fragment 
spanning junction of circRNAs can distinguish translation of circRNA or mRNA 
counterpart. Due to the fact that most of the circRNAs do not associate with 
ribosomes69,82,83,28 and the difficulties in identifying the junction reads of circRNAs from 
Ribo-seq data, circRNAs are considered as a new class of non-coding RNAs. 
Nevertheless, few exceptions are recently reported84–86,87 and a protein product from 
circFBXW7 was indeed shown to have function in glioma tumorigenesis88. 
Although circRNAs do not contain a 5’ cap and a 3’ poly-A tail, they form a circular 
configuration which may favor translation of their embedded ORFs (Fig. 1.3 D). Since 
circRNAs do not contain a 5′ 7-methylguanosine (m7G) cap, translation of circRNAs will 
supposedly follow cap-independent initiation. Especially, during stress, while cap-
dependent is repressed8990, cap-independent translation is favored from the cells91. For 
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examples, during heat shock, cap-independent translation can be driven by N6-
Methyladenosine (m6A)92,93 besides of the use of IRES90.  
It was shown that prokaryotic ribosomes can bind to circRNAs and eukaryotic ribosomes 
can initiate translation of circRNA in vitro79. Later on, a circRNA construct of in vitro 
transcribed GFP ORF, which contained a Shine-Dalgarno sequence, was shown to be 
translated in vivo in E. coli94. This construct produced 30 kDa GFP proteins from 795 nts 
circular mRNA transcript. The author then generated an infinite ORF in the reading frame 
of the initiating AUG by removing its in-frame stop codon. Western blot from E. coli strains 
containing this infinite GFP constructs showed several protein bands ranging in size from 
50 to more than 300 kDa. Therefore, it was suggested that ribosomes can ‘’travel’’ on the 
circRNA for several rounds, at least in the infinite GFP construct94. Such rolling circle 
translation was reported in prokaryotes95, in circular virusoid of the rice yellow mottle virus 
(sobemovirus)85 as well as in living human cells96. It was reported that 220-nts CCC RNA 
from virusoid use the initiation–termination sequence UGAUGA to initiate translation. The 
ribosomes read in two (or three due to read-through mechanism) overlapped reading 
frames leading to new amino acid sequences. Interestingly, no IRES sequences was 
found in front of the AUG or after the termination codon of this circRNA85. A similar 
observation was reported later using infinite Flag construct. This study showed that rolling 
circle translation happens without any specific features96, such as IRES sequences. This 
also confirmed the suggestion that ribosomes can translate a circRNA several rounds94,96.  
Several artificial minigene constructs were used to demonstrate that circRNA can be 
translated in vivo in human cells with or without a functional IRES element55,52,96. Other 
efforts to search for evidence of translation of endogenous circRNAs in mammalian cells 
showed that translation of circRNAs occurs in a very sophisticated and distinct manner 
depending on different circRNAs84,86,87,97. Indeed, translation of circRNAs can be driven by 
m6A84, by IRES87 or coupled with splicing86, all of which using cap-independent 
mechanisms. 
Firstly, since several circRNAs were shown to be m6A methylated98, circRNAs with m6A-
containing short sequence were reported to be translated in cells84. This study showed that 
circRNA translation is promoted by METTL3/METTL14 and further requires eIF4G2 and 
YTHDF3. Furthermore, Mass spectrometry identified several endogenous peptides, which 
are generated from these m6A-containing circRNAs84.  
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Secondly, two studies suggested that circRNAs with IRES sequence can be translated in 
vivo. The first evidence came from circMbl87. This study showed that several circRNAs, 
including abundant circMbl, are associated with translating ribosomes in fly (and therefore 
referred as Ribo-circRNAs). Moreover, they also extended this finding by analyzing 
ribosome profiling data in murine C2C12 cells and rat brain and liver tissues. Interestingly, 
by analyzing such events, it was shown that Ribo-circRNAs are often not among the most 
abundant circRNAs and often share the 5’ UTR and start codon with its linear parental 
mRNAs87. The UTR of circMbl can drive circRNA translation in a cap-independent manner 
and this translation is regulated by starvation and the RBP FOXO87. The second evidence 
of translation of circRNA driven by IRES came from circFBXW7. Translation of circFBXW7 
is initiated via cap-independent manner and gives a novel 21 kDa protein, called FBXW7-
188aa. To the best of my knowledge, this is the first study that showed a function of a 
protein generated from a circRNA. FBXW7-188aa suppresses glioma cell cycle and cell 
proliferation in vitro and in vivo. Specifically, FBXW7-188aa destabilizes c-Myc protein 
through binding to the de-ubiquitinating enzyme USP28. FBXW7-188aa shares N-terminal 
protein sequence with the E3 ligase FBXW7, the most abundant isoform of the FBXW7 
gene. FBXW7 binds to c-Myc via its C-terminal WD40 domain and binds to USP28 at its 
N-terminal domain. Given that USP28 stabilizes c-Myc, FBXW7-188aa competes with 
FBXW7 for binding to USP28 and therefore liberates FBXW7for c-Myc degradation88.  
Finally, another study showed that circRNA translation is dependent on splicing, as 
example of circZfp609 (or circZNF609 in human)86. Using an artificial construct for 
overexpression of circZfp609 with 3xFlag tag, circZfp609 was shown to generated 2 
proteins from this minigene. The UTR of circZfp609 alone does not contain IRES activity 
as by viral IRES from ECMV but circZfp609 UTR rather needs splicing for function as 
IRES. Of notes, the construct circZfp609-3xFlag used in this study was generated by 
myself as part of the PhD project and provided to the Irene Bozzoni lab.  
Such examples suggested us that translation from circRNAs may happen more frequently 
in nature and provide new sources of novel proteins regulating different aspects of 
biological activities. Many bioinformatics tools were developed to predict the availability of 
such translation events99,100,101,102 and more translation studies of circRNAs will 
presumably be reported in the near future. 
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 CircRNA associated with RBPs (circRBPs) 1.4.3
The development of new bioinformatic approaches revealed that certain RNA-binding 
proteins (RBPs) possess a high number of binding sites in circRNA sequences99. Several 
studies showed that circRNAs are specifically bound by RBPs and have different functions 
(Fig. 1.3 E).  
One study showed that circFOXO3 represses cell cycle by forming a circFOXO3-p21-
CDK2 complex, therefore blocking the function of CDK2 and arrest cell cycle 
progression105. Moreover, silencing of circFOXO3 inhibits senescence. Mechanistically, 
circFOXO3 interacts with ID-1 and E2F2 and anti-stress proteins FAK and HIF1α107. 
Furthermore, circFOXO3 overexpression increase apoptosis through upregulation of 
FOXO3 and its downstream target PUMA. Mechanistically, circFOXO3 promotes MDM2-
induced p53 ubiquitination, resulting in p53 degadation108. Another circRNA called 
circAmotl1 contains binding sites for c-Myc. Ectopic expression of circAmotl1 increased c-
Myc retention in the nucleus and promoted c-Myc stability. Normally, c-Myc mainly 
localizes to the cytoplasm, translocating c-Myc to the nucleus promotes tumorigenesis109.  
Other searches for circRBPs show that several circRNAs such as circCDYL, circNFATC3, 
and circANKRD17 were shown to bind to IMP3 proteins using co-IP coupled to RNA-
Seq83. However, the functional consequence of the association of circRNAs with IMP3 is 
not known. Later, circANRIL was shown to bind to pescadillo homologue 1, or PES1, a 
component of a pre-ribosomal assembly complex110. circANRIL prevents rRNA 
maturation by competing for binding sites on PES1 with pre-rRNA. This leads to 
activation of p53 and induction of nucleolar stress and therefore increases cell 
apoptosis110. Such competitive binding was also shown for circPABPN1, which inhibits 
HuR binding to its cognate mRNA PABPN1. Since HuR is a translational activator, this 
competition leads to translation suppression of PABN1106 (Fig. 1.3 G).  
Other study found that overexpressed circZKSCAN1 binds to several RBPs including 
MOV10 or UPF1 and UPF2, components of the non-sense mediated decay pathway or 
YTFDF2, YTFDF3, proteins that read m6A modification111. Interesting, circGFP, which is 
not expressed in human cells but produced by circZKSCAN1 intron, was shown to bind 
to several RBPs, much more than circZKSCAN1 produced from its endogenous intron. 
However, the function of these interactions is not known and would be interesting to 
investigate in the future111.  
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Fig. 1.3: Functions of circRNAs. A) ci-ankrd52 is generated from second intron of the ANKRD52 
gene and is escaped from debranching of its intron lariat. ci-ankrd52 accumulates in the nucleus 
and associates with RNA Pol II to regulate expression of its parental gene ANKRD5242. B) 
circEIF3J is generated from exon with retained intron of the EIF3J gene. It is also accumulated in 
nucleus and interacts with U1 snRNP and RNA Pol II to enhance the transcription of its own gene 
EIF3J43. C) circSEPALLATA3 (or SEP3) is derived from exon 6 of SEPALLATA3 mRNA. It forms 
RNA:DNA hybrid with its parental DNA to regulate the splicing of its cognate SEPALLATA3 
mRNA103. D) Some circRNAs are associated with ribosomes and are proposed to function as 
template for translation86,87. E) Several circRNAs contains binding motifs for several RBPs and 
therefore are thought to function as RBP sponges or scaffold for RBPs104,105. F) Most of circRNAs 
are predominantly localized to the cytoplasm and contain binding sites for miRNAs, and therefore 
are suggested to function as miRNA sponges. For examples, CDR1as (or ciRS-7) contains more 
than 70 binding sites for sponging miR-770,26. G) HuR binds to the 3’ UTR of PABPN1 mRNA and 
enhances PABPN1 mRNA translation. Binding of HuR to circPABPN1 prevents binding of HuR and 
PABPN1 mRNA UTR and therefore decrease the translation of PABPN1 mRNA106.  
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The development of new bioinformatic approaches, such as a database called 
“CircInteractome”99 or circScan100, allows to systematically search for potential 
interactions of circRNA with RBPs. As miRNAs sponges seem to be the common 
features of circRNAs, several circRNAs were shown to bind to Ago2. Consistently, 
CircInteractome and circScan identified several circRNAs-RPBs from CLIP-seq data, 
including Ago299,100. Moreover, as several circRNAs contain m6A modifications98, 
circScan showed that YTHDFs are the proteins that bind to m6A-circRNAs100. 
Interestingly, some of these YTHDFs-bound circRNAs also bind to eIF3 and enrich in 
ribosome-bound fractions suggesting that some of these circRNAs can be translated100. 
In the future, with the efforts in identifying the RBPs of circRNAs, we could understand 
more about the function of circRNAs, apart from miRNA sponges.  
 Other functions of circRNAs 1.4.4
Apart from circRNAs localized to the cytoplasm, which function as miRNA or RBP sponges 
or associated with ribosomes, several circRNAs, mostly intron-containing circRNAs, were 
reported to localize to the nucleus42,43. Many circRNAs are associated with RNA 
polymerase II (Pol-II) polymerase43,42 or form R-loops to regulate transcription of its 
parental genes103.  
The first evidence came from bioinformatics analysis of poly (A) (-) transcriptomes. This 
study identified several circRNAs that come from intron lariat and can escape from 
debranching. One of those called ci-ankrd52 binds to the Pol-II machinery and positively 
enhances the transcription of its host andkrd52 pre-mRNA42 (Fig. 1.3 A). Another study 
identified a class of exon-intron-containing circRNAs, called exon-intron circRNAs or 
EIciRNAs. Since EIciRNAs localize to the nucleus, it was suggested that the RNA-RNA 
interaction between EIciRNAs and U1 snRNAs forms the EIciRNAs-U1 snRNA complexes. 
This complex then interacts with Pol-II transcription machinery to promote gene expression 
(Fig. 1.3 B). For instance, circEIF3J and circPAIP2 were shown to regulate the expression 
of their parental genes43.  
Another example came from circRNA from Arabidopsis thaliana. The circRNAs derived 
from exon 6 of the SEPALLATA3 gene called SEP3 promotes the expression of its 
cognate endogenous mRNA variant SEP3.3 which skips exon 6. Mechanistically, SEP3 
circRNA binds strongly to its DNA locus, forming a RNA-DNA hybrid (Fig. 1.3 C). It is 
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suggested that this R-loop structure may stall the transcription elongation and therefore 
increases the production of exon-skipped transcript variant103.  
1.5 CircRNAs in development and diseases 
Advance in high-throughput technologies has profiled several circRNAs differently 
expressed during different developmental process, differentiation or cancer. A recent study 
published a resource of circRNA expression from 20 human tissues with disease-related 
clinical research29 suggesting that circRNA can be future biomarkers for several diseases 
and potential implications for therapeutic and research applications. Together with other 
studies, it is now clear that the expression of circRNAs is highly regulated in cells and 
show tissue-specific expression patterns. For examples, circRNAs are most abundant in 
brain and regulate ín neuronal plasticity82. Many circRNAs are involved in cardiovascular 
development and pathology as summarized by Li et al., 2017112.  Several circRNAs are 
reported to play important roles in cancer progression and metastasis as summarized by 
Kristensen et al., 2017113. In most of the cases, the functions of circRNAs are related to 
miRNA sponges.  
1.6 Study about circZNF609 and its parental ZNF609 
The first study about zinc-finger protein ZNF609 is from its mouse ortholog, Zfp609114. It 
was shown that Zfp609 is necessary for Rag1 and Rag2 expression in developing 
thymocytes. Zfp608 blocks T-cell maturation by repressing the expression of Zfp609 and 
therefore represses the expression of Rag1 and Rag2114. Recently, Zfp609 was shown to 
bind to Nipbl and the Integrator complex and regulate genes that control neuronal 
migration115.  
CircZfp609 was shown to be upregulated during primary neuron differentiation65 and aging 
of the mouse brain116. Another study showed that the expression of human circZNF609 
(was also called myocardial infarction-associated circular RNA or MICRA)117 in blood 
samples is lower in myocardial infarction patients compared to healthy control samples. 
Moreover, the expression of MICRA in peripheral blood samples of patients with acute 
myocardial infarction could be used for prediction of left ventricular dysfunction. However, 
the mechanism of circZNF609 in these studies is not clear117.   
Two other studies showed that circZNF609 has a function as miRNA sponges118,119 and 
one study showed that circZNF609 is associated with ribosomes and therefore could 
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encode for protein86. First of all, circZNF609 was reported to be down-regulated in 
Hirschsprung disease compared with normal bowel tissues. Hirschsprung disease is a 
developmental defect of the enteric nervous system characterized by lack of enteric 
neurons in the distal hindgut120. This is because the migration of the nerve cells from 
neural crest is not complete and therefore the activity of colon is not normal. Indeed, this 
study showed that depletion of circZNF609 inhibited cell proliferation and migration. 
Mechanistically, circZNF609 may act as a sponge for miR-150-5p to modulate the 
expression of AKT3118. Second, circZNF609 was reported to be upregulated during 
glucose and hypoxia stress in vitro and in vivo. In contrast to the previous study, 
knockdown of circZNF609 increases endothelial cell migration and therefore increase tube 
formation. To understand its mechanism, it was shown that circZNF609 sequesters and 
inhibits miR-615-5p activity, leading to increasing expression of MEF2A119. Further study 
showed that circZfp609 (and human circZNF609) is downregulated during muscle 
differentiation and may encode for a protein. This study proposed that circZfp609 and its 
protein products may function in regulating myogenesis86.  
1.7 Colorectal cancer progression and metastasis 
Colorectal cancer (CRC) accounts for about 1.4 million newly diagnosed cases every year, 
making it the third most commonly diagnosed malignancy worldwide as reported in 
2012121,122. Over the past few decades, several studies have revealed several key 
oncogenes and tumor suppressor genes, especially the APC, KRAS, and p53 genes, are 
frequently mutated in CRC samples123,124,125. For instances, hyperactivation the Wnt 
pathway, which predominantly occurs through inactivation of the APC gene, drives the 
transition from normal epithelium to benign adenoma of CRC126,127. Liver metastases of 
CRC occur in about 50% of patients and are the major cause of CRC‐related mortality. 
However, the molecular alterations that support metastases are poorly understood128,129.  
CRC metastases were first proposed to progress through a clonal tumor evolution process 
which invasive carcinomas arise from adenomas through the sequential accumulation of 
mutations in several key genes130. Indeed, several mutational profiles of metastases in 
comparison to primary tumors have shown high concordance between both 
processes131,132. However, conflicting results have been recently reported in some studies 
showing high discordance mutational rate. For examples, one studies show that in the ten 
discordant cases reported, 50% of patients whose primary tumor was wild-type had a 
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mutation in the metastasis while other 50% of patients showed a mutation in primary tumor 
but not in metastases133,134. Indeed, several studies, especially in breast cancer, have 
recently challenged the generally accepted model for tumor progression through clonal 
evolution. For examples, there is evidence that metastases can originate parallel with 
primary tumors135,136 given that there are several early origins of metastatic lineages 
already in primary tumors137,138.  
 
Fig. 1.4: Stepwise (late dissemination) and parallel (early dissemination) models of tumor 
progression during cancer metastasis. In the stepwise progression, metastases are 
disseminated at the late stage of tumour development and therefore, the late-disseminated cells 
and primary tumors are genetically similar. On the other hand, in the parallel progression, the 
disseminated cells are evolved early and accumulate different genetic and epigenetic alterations 
and consequently diverge from primary tumors. Understanding the origin of cancer dissemination 
and metastasis cascades may contribute to a better diagnosis and design of effective therapies. 
Figure adapted from139. 
With the development of RNASeq technologies, abnormalities of non-coding RNA 
expression were found to be associated with CRC pathogenesis. Indeed, accumulating 
evidence has suggested that miRNAs and lncRNAs are involved CRC metastasis by 
acting as epigenetic, splicing, transcriptional or post-transcriptional regulators140,141. Very 
recently, several circRNAs were found to be differentially expressed in different stages of 
CRC suggesting that circRNAs could also play important roles in the progression and 
metastasis of CRC. Therefore, a better understanding of the expression and function of 
these non-coding RNA molecules might provide opportunities for understanding the early 
versus late dissemination mechanisms of CRC metastasis.  
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1.8 Aim of this thesis 
Several studies showed the important involvement of lncRNAs and miRNAs during 
colorectal cancer progression and metastasis. However, at the time of starting this PhD 
thesis, nothing was known about the roles of circRNAs in development and cancer, 
especially colorectal cancer. The first aim was to profile the differentially expressed 
circRNAs in colorectal cancer progression and metastasis. RNAseq was performed using 
HT29.hCG.Luc intrasplenic SCID mouse model.  
With the set of several circRNAs showing differential expression in primary tumors or liver 
metastases from RNAseq, further investigation revealed that one specific circRNA called 
circZNF609 is upregulated during cancer progression whereas its linear counterpart, 
ZNF609 mRNA is not. A further aim of this thesis was to characterize circZNF609 and 
understand its mechanism in colon cancer progression.  
During the course of this PhD thesis, Irene Bozzoni group showed that circZNF609 is 
associated with ribosomes and may encode for proteins. Therefore, the last aim was to 
understand how the translation of circZNF609 occurs. This could shed lights on 
understanding the initiation mechanism of circRNA translation, which is poorly understood 
compared to the well-studied mRNA translation.  
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2 Results 
2.1 Mouse model and RNAseq analysis for detection of 
circRNAs 
To identify circRNAs, we generated a mouse model for colorectal cancer development and 
metastasis (Fig. 2.1 A). Specifically, the human colon cancer cell line HT29 expressing 
both luciferase and human chorionic gonadotropin (HT29.hCG.Luc) were intrasplenically 
injected into 6 weeks-aged female CB17 severe combined immunodeficient (CB17.SCID) 
mice. HT29.hCG.Luc, HCT116.hCG.Luc and CMT93.hCG.Luc were generated as 
described previously142. In this study, we took advantages of bioluminescence (using 
luciferase) and-hCG as noninvasive quantification method for monitoring tumour burden. 
As reported previously in several studies, the relative levels of these surrogate tumour 
markers were proved to be a stable indicator of tumour burden143.  Primary tumors and 
liver metastases were resected about 4-6 weeks after injection when bioluminescence 
levels reached about 500.000 photons/s. The RNA from HT29.hCG.Luc, primary tumors 
and liver metastasis was extracted. After quality control of the RNA using Bioanalyzer, 
miRNA library was prepared using the TrueSeq Small RNA Sample Prep while rRNA-
depleted transcriptome library was prepared using the NuGEN paired-end strand-specific 
RNASeq system.  
Bioinformatics analysis for identification and quantification of circRNA expression was 
performed in collaboration with the laboratory of Nikolaus Rajewsky. We followed methods 
of identifying the head-to-tail splice junction from RNA sequencing reads as described 
before26. Using this strategy, we have identified several circRNAs differentially expressed 
in our mouse model (Fig. 2.1 B). Interestingly, several circRNAs showed differential 
expression while their cognate mRNAs did not change (Fig. 2.1 C). One of the circRNA 
candidates we would like to characterize further is circZNF609, which is upregulated in 
primary tumor and liver metastasis from our mouse model.  
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Fig. 2.1. Identification of circRNAs from HT29.hCG.Luc/SCID mouse mode. A) Mouse model 
for miRNA and circRNA library preparation. B) Differential expression of circRNAs in liver 
metastasis versus HT29.hCG.Luc. The total number of reads supporting a particular head-to-tail 
junction was used as an absolute measure of circRNA abundance. C) Scatter plot of circRNA 
expression and linear transcript expression in liver metastasis versus HT29.hCG.Luc. Expression 
of some circRNAs is independent from its hots gene.  
2.2 Characterization of circZNF609 
CircZNF609 is a 874 nucleotides (nts) long RNA and represents a circularized exon of 
ZNF609 mRNA. It is generated by a back-splicing event of exon 2 of ZNF609 (Fig. 2.2 A). 
CircZNF609 shares AUG with its cognate mRNA ZNF609. Interestingly, we found a stop 
codon upstream of the circZNF609 AUG which could generate a complete open reading 
frame (ORF) upon circularization (Fig. 2.2 A).  
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Fig. 2.2. Characterization of circZNF609. A) Scheme indicates the ZNF609 locus with 
circZNF609 generated from its exon 2. The circularized exon 2 of circZNF609 is located between 
very long introns as observed for several circRNAs. The stop codon (red color) locates in front of 
the start codon AUG (green color). Upon circularization, circZNF609 forms a complete ORF and a 
5’ UTR (yellow color) locates between the stop and start codon. B) Relative expression of 
circZNF609 in primary tumor (PT) and liver metastasis (LM) validated by qPCR. The relative 
expression of circZNF609 was normalized to the expression of GAPDH and its host gene, ZNF609 
mRNA, respectively. C) Total RNA from HT29.hCG.Luc treated with RNase R (lane 2) or mock 
treated (lane 1) were loaded on agarose gel. Northern blot analysis of circZNF609 after RNase R 
treatment (lane 4) showed significant levels of circZNF609. 
Validation of the expression of circZNF609 in our mouse model by qPCR confirmed that 
circZNF609 is upregulated during cancer progression while the expression of ZNF609 
mRNA is unchanged (Fig. 2.2B). To further confirm the circularity of circZNF609, we used 
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RNase R, a 3′ to 5′ exoribonuclease35, to digest all linear RNAs. Northern blot showed that 
circZNF609 is resistant to RNase R treatment confirming the circular nature of this 
molecule (Fig. 2.2 C). Further characterization revealed that circZNF609 is not enriched in 
poly (A) (+) fraction as observed for the ZNF609 mRNA (Supplemental Fig. 5.9 A), 
indicating that circZNF609 is indeed a circle.  
Taken together, we have identified and confirmed that circZNF609 is a circular RNA and is 
upregulated during colorectal cancer progression and metastasis. Further functional 
experiments would be needed to understand the significance of circZNF609 upregulation 
in CRC progression.  
2.3 Generation of shRNA constructs targeting circZNF609 
To investigate the potential function of circZNF609 on CRC development, we performed 
the knockdown experiments. Therefore, we designed an siRNA for knocking down of 
circZNF609.  Since circZNF609 shares its sequence with ZNF609 mRNA, the siRNA was 
designed to target the junction of circZNF609 (Fig. 2.3 B). qPCR from HT29.hCG.Luc and 
HEK293T cell lines transfected with the designed siRNA showed that this siRNA can 
specifically target circZNF609 without affecting the expression of ZNF609 (Fig. 2.3 A).  
To study the impact of circZNF609 on primary tumor and metastasis development in vivo, 
we wanted to generate a stable HT29.hCG.Luc cell line, which itself can produce siRNAs 
to knock down circZNF609 upon doxycycline induction. This is critical because we can 
manipulate the expression of circZNF609 after the cells have been implanted into the 
mice.  
To achieve silencing of circZNF609 via shRNA, a pSuper vector was used. Correct shRNA 
synthesis and processing was verified by northern blot using total RNA isolated from 
HEK293T cells. At first, it is worth mentioning that the stop signal for transcription of the H1 
promoter, which is RNA polymerase III (Pol-III) promoter, is determined by five Ts in a row 
(TTTTT). Unfortunately, due to the fact that the designed sequences had to comprise a 
number of nucleotides in the junction of circZNF609, all of our constructs contained four Ts 
in a row in front of the stop signal likely causing premature abortion of Pol-III transcription 
(Fig. 2.3 B). As expected, northern blot analysis revealed no significant expression of the 
siRNA from the pSuper constructs (data not shown). 
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Fig. 2.3. Generation of shRNA constructs targeting circZNF609. A) HEK293T or 
HT29.hCG.Luc was transfected with siRNA targeting circZNF609. 3 days post-transfection, the 
RNA was harvested for qPCR analysis. B) siRNA strategy for targeting circZNF609. Alignment of 
the siRNA with junction of circZNF609 is indicated. All 3 designed sequences spanning the junction 
of circZNF609 contain four Ts in a row in front of the stop signal, therefore lead to premature 
abortion of Pol-III transcription. Alternatively, artificial microRNA (amiRNA) construct based on pri-
miR-331 driven by Pol-II promoter was developed. C) HEK293T was transfected with the 
constructs consecutively expressing pri-miR-331 or different amiRNAs. 2 days post-transfection, 
RNA was harvested for northern blot analysis using probes targeting the desired sequence of 
shRNA 03. D) HEK293T was transfected with these amiRNAs constructs using Lipofectamine 
2000. 3 days post-transfection, the RNA was harvested for qPCR analysis. The relative expression 
of circZNF609 and ZNF609 was normalized to the expression of GAPDH 
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Fig. 2.4. Characterization of the amiRNA 03 for establishing the inducible cell line. A) 
HEK293T was transfected with amiRNA 03. 2 days post-transfection, the cells were harvested for 
Ago2 IP using the anti-Ago2 antibodies (clone 11A9). B) The RNA from (A) was run on 12% Urea 
PAGE for northern blot analysis. Let7a was used as positive control. C) Inducible vector for 
expression of shRNA targeting circZNF609. D) HEK293T-sh-circZNF609 was induced with 
doxycycline for 3 days. Afterwards, the cells were harvested for northern blot analysis to confirm 
the expression of amiRNA 03. E) Relative expression of circZNF609 and ZNF609 in HEK293T-sh-
circZNF609 upon doxycycline induction validated by qPCR. The relative expression of circZNF609 
and ZNF609 was normalized to the expression of GAPDH. Dox: Doxycycline 
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To overcome this problem, we designed an artificial microRNA (amiRNAs) construct based 
on pri-miR-331 that is driven by the CMV promoter, which is RNA Pol-II promoter. We 
designed 3 shRNAs spanning the junction of circZNF609 (Fig. 2.3 B). Analysis by northern 
blot revealed that all three antisense strands were produced in a correct manner and 
showed good expression of around 21 nts (Fig. 2.3 C). The data also showed that the 
probe shRNA 03 binds not only amiRNA 03 (Fig. 2.3 C, lane 6) but also the other two 
amiRNAs (Fig. 2.3 C, lane 4, 5). This effect is based on the high sequence similarities of 
the constructs due to the low variety in the design of the different shRNAs, as they were 
designed in a manner to overlay the junction of the circZNF609. qPCR analysis of 
circZNF609 expression three days post transfection of these amiRNA constructs in 
HEK293T cells showed that amiRNA 03 leads to downregulation of circZNF609 
expression without affecting the expression of ZNF609 (Fig. 2.3 D). Of note, by moving 
few nts from the junction, the amiRNA 02 targets only ZNF609, but not circZNF609 (Fig. 
2.3 D). Therefore, amiRNA 03 was selected for further analysis. Further investigation 
revealed that the generated siRNAs from amiRNA 03 are loaded into Ago2 (Fig. 2.4 A, B). 
This implied that the siRNAs generated from this pri-miR-331 are functional.  
To generate the stable inducible cell lines expressing shRNA constructs, the CMV 
promoter (Fig. 2.3 A)  was replaced by the inducible TRE3GS promoter (Fig. 2.4 C). Using 
this vector, we could obtain stable cell lines HEK293T (Fig. 2.4 D, E) expressing shRNA 
(HEK293T-sh-circZNF609). Upon induction with doxycycline, HEK293T-sh-circZNF609 
expresses siRNA targeting circZNF609 (Fig. 2.4 D). Consequently, upon doxycycline 
induction we could knock down circZNF609 without affecting the expression of ZNF609 
(Fig. 2.4 D).  
Collectively, we could develop a construct for specifically targeting circZNF609 without 
targeting ZNF609 in an inducible manner. Then, we could generate an inducible stable cell 
line HEK293T-sh-circZNF609 for knocking down of circZNF609 upon doxycycline 
induction. This is fundamental for establishing inducible stable cancer cell lines to study 
circZNF609’s roles during colorectal cancer progression. 
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2.4 Methods for overexpression of circZNF609 
 
Fig. 2.5. Generation of overexpression constructs for circZfp609. A) Scheme of constructs 
generated for overexpression of circZfp609, the mouse ortholog of human circZNF609. 
Specifically, circZfp609 was produced from plasmids circZfp609i as described in Hansen et al., 
2013 (Kjems lab) or plasmid ZK-circZfp609 using circZKSCAN1 intron as described in Kramer et 
al., 2015 (Willusz lab)52. 3xFlag was inserted in front of the stop codon of circZfp609 to generate 
circZfp609i-3xFlag and ZK-circZfp609-3xFlag plasmids. B) HEK293T cells transfected with 
different overexpression constructs was analysed by northern blot. C) Western blot of HEK293T 
cells transfected with different constructs from (B) detected by anti-Flag antibodies. D) The RNA 
from HEK293T cells transfected with ZK-circZfp609-3xFlag plasmids were harvested and 
subjected to RNase R digestion with different time points.  
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To be able to overexpress circRNAs and to study phenotypes resulting from 
overexpressed circZNF609, we used different methods based on published data70,52. First, 
we decided to overexpress the mouse version of the human circZNF609 (circZfp609). This 
is because we wanted to check the fidelity of overexpressed murine circZfp609 in human 
HEK293T cell lines. Northern blot analysis confirmed expression of the overexpressed 
circZfp609 when comparing with the endogenous circZfp609 (Fig 2.5 B). Moreover, we 
also confirmed the conclusion from the Willusz lab that the method developed by Willusz 
lab52 is much more efficient in producing circRNAs compared to the method from Kjems 
lab70.  
To further confirm the fidelity of overexpressed circRNAs, we digested the RNA with 
RNase R at different time points and observed that the circZfp609 was stable while other 
linear RNAs and processing intermediates were digested (Fig. 2.5 D). To have a solid 
conclusion about the correct circRNA expression, we validated the overexpressed murine 
circZfp609 in HEK293T cells by Sanger sequencing. Even though circZNF609 is highly 
conserved, there are few mismatches in the sequence spanning the junction of circZfp609 
and circZNF609 (Supplemental Fig. 5.9 C). Therefore, Sanger sequencing confirmed the 
expression of murine circZfp609 in human HEK293T cells (data not shown).  
Taken together, we have successfully established molecular tools to overexpress and 
deplete circZNF609. These tools are necessary to understand the mechanisms of 
circZNF609.  
2.5 CircZNF609 potentially encodes for proteins 
 Flag reporter constructs and mutagenesis 2.5.1
During the course of this study, Irene Bozzoni’s lab reported that circZNF609 is bound to 
ribosomes and therefore potentially encodes for small protein(s)86. To investigate this 
hypothesis, a 3xFlag tag was inserted in front of the stop codon of circZfp609. Northern 
blot confirmed that circZfp609 with 3xFlag tag is generated (Fig. 2.5 B, lane 10). This 
construct was then used and validated further in the mentioned publication by the Bozzoni 
lab86. Consistent with the data from the Bozzoni lab, western blot with anti-Flag antibodies 
showed two protein products implying that two AUGs could be used from circZfp609 (Fig. 
2.5 C). Indeed, two AUGs are present that would explain the two protein bands (Fig. 2.5 
C).  Interestingly, we used two different vectors containing different intron sequences 
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(upstream and downstream of circZfp609) for overexpression of circZfp609-3xFlag (Fig 2.5 
A). Both overexpression constructs gave us two protein products confirming that both 
protein products are generated from circZfp609-3xFlag. Notably, the relative expression of 
circZfp609-3xFlag transcripts was less produced from circZfp609i-3xFlag plasmids (Fig 2.5 
B, lane 7) than from ZK-circZfp609-3xFlag plasmids (Fig 2.5 B, lane 10). Consequently, 
the two protein products were less produced from circZfp609i-3xFlag plasmids (Fig 2.5 C, 
lane 5) compared to ZK-circZfp609-3xFlag plasmids (Fig 2.5 C, lane 8).  
To prove that two AUGs from circZfp609 were used for translation, the first or second AUG 
was mutated to CUG (Fig 2.6 A, lane 4, 5) or the first AUG was mutated to UG (Fig 2.6 A, 
lane 6).  Northern blot confirmed the expression of these mutants (Fig 2.6 A) and western 
blot confirmed the usage of those AUG accordingly (Fig 2.6 B). Specifically, when the first 
AUG was mutated to CUG (Fig 2.6 B, lane 3) or mutated to UG (Fig 2.6 B, lane 5) we did 
not observe the expression of upper protein products. When the second AUG was mutated 
to CUG, the lower protein products were not produced (Fig 2.6 B, lane 4).  Interestingly, 
we observed that a third AUG is used when the first AUG is mutated (Fig 2.6 B, lane 3, 5 
and Fig 2.6 C). While two AUGs are normally used from circZfp609, all three AUGs are 
used from circZfp609 when we lengthened the sequence of 5’UTR of circZfp609 (Fig. 2.10 
A and Fig. 2.10 B, lane 3). In this case, we added 49 nts unrelated sequence (49 nts of -
globin UTR) just in front of the first AUG. Western blot showed three protein bands 
corresponding to three observed AUGs on circZfp609 (Fig. 2.10 B, lane 3). Further 
experiments are required to understand the mechanism of how three AUGs are used for 
translation.   
It was reported that, in some plasmids, rolling circle transcription can occur due to the fact 
that the RNA polymerase can sometimes bypass the termination signal. This leads to 
production of several unwanted transcripts, including a precursor transcript containing 
tandem repeats of the circularized exon. These transcripts are suggested to be spliced 
canonically and a linear concatamer of the circularized exon are generated144. In this case, 
the concatamer represents the junction of circRNA, which could be used for translation 
(Fig. 2.7 A) and therefore the protein products that we observed could be unspecific.  
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Fig. 2.6. Mutagenesis of AUGs for understanding translation of circZfp609. A) Northern blot of 
RNA isolated from HEK293T cells transfected with different overexpressed circZfp609 AUG 
mutants. GAPDH served as loading control. B) Western blot of the mutants from (A) detected by 
anti-Flag antibodies. The third AUG is used only when the first AUG is mutated to ACG (lane 3) or 
to UG (lane 5). C) Analysis of circZfp609 sequence predicts 3 AUGs in-frame with 3xFlag and thus 
could be detected by anti-Flag antibodies.  
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Fig. 2.7. Confirmation of circZNF609 translation. A) Scheme of proposed rolling circle 
transcription and generation of linear concatamer. B) Northern blot of transfected fragments from 
plasmids ZK-circZfp609-3xFlag digested with XhoI and BglII. C) Western blot of the HEK293T cells 
transfected with according digested ZK-circZfp609-3xFlag.  
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Fig. 2.8. Deletion of splice site abrogates circZfp609 production and its corresponding 
proteins. A) Scheme represents deletion of splice sites (SS) for disruption of circZfp609 
production. Shown here are examples of ZK-circZfp609. Same delSS was performed with ZK-
circZfp609-3xFlag. Specifically, in this delSS mutant, 3 nts SS (GUA) in the intron of circZKSCAN1 
was deleted. B) Northern blot of all transfected mutants in HEK293T cells. C) Western blot of 
HEK293T transfected with SS-depleted mutants by anti-Flag and anti-Zfp609 antibodies.  
Even though the pcDNA3.1 (+) plasmids contain a strong bGH poly (A) stop signal, we 
wanted to test if the proteins generated from this plasmids are from the concatamer. To 
address this, the plasmids were digested into half by BglII and XhoI. The fragments 
containing the circZfp609 flanking by circZKSCAN1 intron were purified from Agarose gel. 
Northern blot showed the expression of circZfp609 from these fragments (Fig. 2.7 B). 
Western blot from the transfected fragments gave 2 protein products recognized by the 
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anti-Flag antibodies (Fig. 2.7 C). This confirmed that the protein products are generated 
from the circRNAs, not from the concatamer.  
To further confirm that the protein products were produced from circRNAs, we disrupted 
the production the circRNAs by deleting 3 nts of the splice site (GUA) from the 
circZKSCAN1 right intron (Fig. 2.8 A). Since GU and AG dinucleotides are important splice 
sites for splicing145, deletion of 3 nts GUA may abrogate the back-splicing of circZfp609. 
Indeed, northern blot showed that circRNAs were not made from the cells, only the linear 
RNAs (Fig. 2.8 B). Consequently, we did not observe any proteins from the ZK-circZfp609-
3xFlag-delSS mutant using anti-Flag antibodies (Fig. 2.8C) confirming that the proteins are 
indeed produced from circRNAs, not from any linear RNA, which is generated during the 
circRNA biogenesis process.  
To search for a potential IRES sequence which may contribute to the recruitment of 
ribosomes for translation, we analyzed the 5’UTR of circZfp609 since this is the region 
where IRES elements are often located in other RNAs (Fig. 2.9 A). Mutagenesis was 
performed with different truncations of the 5’UTR (Fig. 2.9 B). Importantly, deletion of 121 
nts 5’UTR (Del 121) showed only one protein band while Del 121-A did not give us any 
protein products recognized by the anti-Flag antibodies (Fig. 2.9 D). Of note, northern blot 
confirmed that all truncated mutants produce circZfp609-3xFlag in HEK293T cells (Fig. 2.9 
C).   
Deletion of 89 nts 5’UTR (Del 89) still gave us 2 protein bands (Fig. 2.9 C) implying that 
the IRES sequence may locate in the last 32 nts of 5’UTR. Several other mutants of these 
32 nts of 5’UTR were generated (Fig. 2.10 and Supplemental Fig. 5.11 and 5.12) and 
western blot revealed different protein products for different mutants (Fig. 2.10 B). 
Specifically, the Del 101 mutant still gave two protein products while the other mutant (Del 
89 & Del 111-121, Fig. 2.10 B, lane 8) did not produce these two protein products, but a 
fainted higher molecular weight protein product. The result from these mutants implied that 
32 nts of 5’UTR does not contain the IRES element and consequently, the 5’UTR does not 
function as IRES for translation of circZfp609. Therefore, the IRES sequence of circZfp609 
may locate in its coding sequence. Further experiments and mutagenesis would be 
required to conclude this hypothesis.  
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Fig. 2.9. Mutagenesis of Zfp609 UTR for studying its translation mechanism. A) Scheme of 
121 nts of circZfp609 5’ UTR in between the stop codon UGA and the first start codon AUG. B) 
Truncated mutants of circZfp609 5’ UTR. C) Northern blot of HEK293T cells transfected with all 5’ 
UTR deletion mutants show expression of overexpressed circZfp609 5’ UTR mutants. D) Western 
blot of samples from C) using anti-Flag antibodies.  
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Fig. 2.10. Further analysis of Zfp609 5’ UTR. A) Truncated mutants of circZfp609 5’ UTR were 
generated to understand how circZfp609 can recruit the ribosome. 49 nts of the -globin UTR was 
inserted before the AUG of circZfp609. In this case, we observed all 3 AUGs are used for 
translation. Del 89 represents several A could potentially m6A methylated as suggested from 
RMbase146. All 3 As were mutated to Us or all 3As were deleted. For translation of circRNA, it is 
very important to delete 3 nts or sequentially each nucleotide because of the frameshift as 
discussed. B) Western blot of the HEK293T cells transfected with different mutants by anti-Flag 
antibodies. Arrow indicates the proteins products.  
To understand the protein products generated from these above mutants, we proposed 
that, on a circle, translation of circZfp609 is shifted to different ORFs when the 5’UTR or 
different parts of the 5’UTR are deleted. To check this hypothesis, we generated other 
mutants where we deleted sequentially one, two and three nts of Del121 constructs (Fig. 
2.11 A). If our hypothesis is correct, we will observe the same protein products from Del 
121 and Del 121-AUG mutants. Indeed, northern blot confirmed the expression of all 
deletion mutants (Fig. 2.11 B) and western blot using anti-Flag antibodies revealed that 
Del121-AUG give us the same protein bands (Fig. 2.11 C, lane 4)  as observed for Del121 
(Fig. 2.11 C, lane 7).  
Unexpectedly, we observed higher molecular weight protein products of the Del121-AU 
mutants than the two normal protein products produced from ZK-circZfp609-3xFlag (Fig. 
2.11 C, lane 6). The result from this Del121-AU mutant implied that there are other 
upstream AUGs, which could be used for translation. Importantly, these protein products 
were recognized by anti-Flag antibodies meaning that the Del121-AU starts translation at 
upstream AUGs and ends at the 3xFlag (Fig. 2.11 D). Moreover, in this case, we did not 
observe the two normal protein products as observed for ZK-circZfp609-3xFlag. This could 
be explained as following: when the upstream AUGs are used for translation, the 
downstream AUGs (in this case, the two normal AUGs) from circZfp609 are not used any 
more. Moreover, we did not observe any protein products from Del 121-A mutants (Fig. 
2.11 D). In this case, this could be explained by two possibilities: either the upstream 
AUGs or the two normal AUGs were used for translation but, in both cases, their ORFs did 
not end at the 3xFlag frame. Therefore, we did not observe any protein products 
recognized by anti-Flag antibodies. In summary, these mutants confirmed that there was a 
frame change on circZfp609 when one nucleotide is deleted from Del 121.  
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Fig. 2.11. Translation of circZfp609. A) Mutagenesis of each one nucleotide from Del 121 for 
understanding its translation. B) Northern blot of HEK293T cells transfected with all truncated 
mutants showed significant expression of the overexpressed circZfp609. C) Western blot of 
deletion mutants using anti-Flag antibodies. D) Sequence of 3x Flag contains 4 AUGs, which can 
be used for translation of circZfp609.  
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To further understand the protein products generated from Del 121-AU mutant, we 
analyzed the upstream sequence of its 5’ UTR. Unexpectedly, analysis of the sequence 
from circZfp609-3xFlag revealed four out-of-Flag-frame AUGs in the 3xFlag sequence and 
we proposed that these four AUGs are used for translation when the normal circZfp609 
ORF is shifted (Fig. 2.11 D). Further mutagenesis of these mutants is required to have a 
solid conclusion about this observation.  
Taken together, mutagenesis of 5’ UTR of circZfp609 showed that this 5’ UTR does not 
contain IRES elements. Furthermore, the translation of circZfp609 is possible and several 
AUGs can be used for translation on circZfp609. The mechanisms of how different AUGs 
were used are still not known and further analysis is required for a final conclusion. All 
western blots in these experiments were performed using anti-Flag antibodies, further 
western blot analysis using anti-Zfp609 antibodies is necessary for better understanding of 
circZfp609 proteins and translation mechanisms.  
 Detection of circZfp609 proteins by anti-Zfp609 antibodies 2.5.2
Since the overexpression of circZfp609 proteins from the mentioned vectors gave several 
products, it is essential to analyze circZfp609 translation under physiological condition. As 
a first approach, we analyzed the expression of circZfp609 proteins in a stable cell line 
using anti-Zfp609 antibodies. For in vivo xenograft study (see 2.8), we developed an 
inducible stable cell line for overexpression of circZfp609 upon doxycycline induction 
(CMT93-circZfp609) (Fig. 2.12 B). Using anti-Zfp609 antibodies to detect circZfp609 
proteins, western blot from this CMT93-circZfp609 stable cell line upon doxycycline 
induction showed at least 2 protein bands recognized by anti-Zfp609 antibodies (Fig. 2.12 
B, lane 4). One protein band has similar size with proposed endogenous protein (Fig. 2.12 
B, lane 3). Unexpectedly, we observed two more protein bands which are only expressed 
in the CMT93-circZfp609 cells upon doxycycline induction (Fig. 2.12 B, lane 3). 
To understand the expression of these additional protein bands, we noticed that there are 
at least two RNA products generated from circZfp609 overexpression vectors (Fig. 2.12 
A). Specifically, after transcription, in addition to the circZfp609 transcript, a linear 
transcript was also produced (Fig. 2.12 A). The linear transcript shares its sequence with 
circZfp609 transcript. The only difference between circZfp609 transcript and the linear 
transcript is the usage of stop codon. As mentioned before, circZfp609 transcript uses an 
upstream stop codon upon circularization. On the other hand, the linear transcript uses a 
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stop codon from the circZKSCAN1 intron, which is downstream of the circZfp609 exon 
(Fig. 2.12 A). Since both transcripts contain similar sequence, their protein products are 
both recognized by the anti-Zfp609 antibodies. Therefore, there are more protein products 
are detected in western blot using the anti-Zfp609 antibodies.  
To further prove that the linear transcripts from overexpression vectors could be used for 
translation, 3xFlag sequence was inserted just after the first AUG of circZfp609 (Fig. 2.12 
C) instead of in front of stop codon as described in ZK-circZfp609-3xFlag (Fig. 2.5 A).  
Western blot using anti-Flag antibodies showed two proteins products corresponding to 
two transcripts: one belongs to the circRNA transcript and another one belongs to the 
linear RNA transcript (Fig. 2.12 D).  
In the same line with this observation, western blot of HEK293T cells transiently 
transfected with ZK-circZfp609 and ZK-circZfp609-3xFlag using anti-Zfp609 antibodies 
revealed several proteins products (at least 4 main products) (Fig. 2.8 C). As described 
previously, two AUGs were normally used for translation from circZfp609, giving two 
protein products. Since the linear transcripts share these two AUGs with circZfp609, these 
two AUGs could be used for translation as well. Consequently, translation of these 
transcripts resulted four protein products recognized by the anti-Zfp609 antibodies.  
To further examine this conclusion, western blot of HEK293T cells transfected with delSS 
mutants (ZK-circZfp609-delSS and ZK-circZfp609-3xFlag-delSS) was performed (Fig. 2.8 
C). Notably, these delSS mutants do not express circular transcripts and therefore the anti-
Zfp609 antibodies only detect protein products generated from linear transcripts. Indeed, 
both delSS mutants (ZK-circZfp609-delSS and ZK-circZfp609-3xFlag-delSS) gave only 
two proteins products. This indicated that these two protein products came from linear 
RNAs. The other missing products were generated from the circular RNAs (Fig. 2.8 C).  
In conclusion, western blot analysis of proteins generated from overexpression vectors 
using the anti-Flag antibodies revealed two protein products while four protein products 
were recognized using the anti-Zfp609 antibodies. At the endogenous level, we only 
observed one protein product. Furthermore, since several transcripts were generated from 
the overexpression vectors, analysis of a single circle transcript using synthetic circRNA is 
required for a convincing conclusion about the translation of circZfp609.  
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Fig. 2.12. Several proteins are produced from overexpression constructs. A) Northern blot of 
inducible stable cell lines CMT93.hCG.Luc expressing circZfp609 upon doxycycline induction 
(CMT93-circZfp609). B) Western blot of CMT93-circZfp609 cells upon doxycycline induction 
detected by anti-Zfp609 antibodies. C) Scheme of ZK-circZfp609-3xFlag-First AUG construct. A 
stop codon in the circZKSCAN1 intron downstream of circZfp609 can be used to generate a 
complete ORF. D) Western blot of HEK293T cells transfected with of ZK-circZfp609-3xFlag-First 
AUG by anti-Flag antibodies.  
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2.6 Synthesis of circZNF609 in vitro 
As result from overexpression plasmids gave us several protein products recognized by 
the anti-Zfp609 antibodies, thus further investigation using synthetic circZNF609 are 
necessary to shed light on its translation mechanism. For this purpose, we performed 
circZNF609 synthesis in vitro (hereafter, we call it synthetic circZNF609) by the permuted 
intron-exon (PIE) method. Such studies exclude any protein bands that could be 
generated by the linear processing intermediates.  
 PIE system for in vitro transcription (IVT) of circRNAs 2.6.1
Initially, we tried to obtain synthetic circZNF609 using T7 promoter followed by RNA 
ligation. However, this method required several steps147 and the circZNF609 can only be 
distinguished by running on denaturing urea polyacrylamide gel electrophoresis (Urea 
PAGE), which was proved to be very tricky (data not shown). To get better preparation for 
circZNF609, we used the PIE method. In order to test the PIE method, we followed the So 
Umekage’s approach148 (Fig. 2.13 A) using the pGEM-3E5-T7t vector. In this vector, the 
PIE sequence was used to produce streptavidin circular RNAs both in vitro and in vivo in 
E. coli148. The PIE sequence of the pGEM-3E5-T7t vector is formed by a 3’ half intron, the 
streptavidin aptamer (as circularized test gene) and a 5’ half intron (Fig. 2.13 A). This is 
the configuration necessary to achieve self-splicing and circularization148. Moreover, the 
PIE sequence is flanked by a T7 promoter and a T7 terminator, which allow for performing 
circularization in vivo148. The IVT of PIE method requires Mg2+ and guanosine nucleotides 
as indispensable components for splicing149,148. 
To set up in vitro circRNA generation as described, we deleted the aptamer sequence 
from the vector to obtain a new plasmid, pGEM-3E5-T7t-apdel, which served as a negative 
control for the self-splicing reaction. We performed the IVT with an additional incubation at 
55°C for 30 minutes to enhance the RNA circularization. Afterwards, the synthesized 
RNAs were separated onto a 6% urea PAGE (Fig. 2.13 B). EtBr straining revealed the 
expected bands corresponding to the aptamer circRNAs from pGEM-3E5-T7t and this 
band was abolished in the negative control of IVT transcribed from plasmids pGEM-
3E5T7t-apdel (Fig. 2.13 B). 
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Fig. 2.13. The PIE method for production of streptavidin circular aptamer. A) Scheme of the 
pGEM-3E5-T7t vector containing all necessary sequence for PIE method148. The PIE is located 
between the T7 promoter sequence and the T7 terminator sequence for in vivo production of 
circRNAs in E. coli. The PIE sequence consists of the 3’ half intron, streptavidin aptamer sequence 
and the 5’ half intron sequence148. B) Urea PAGE of IVT from pGEM-3E5-T7t (Lane 2) and pGEM-
3E5-T7t-apdel (Lane 3) plasmids.  
 IVT for circZNF609 synthesis 2.6.2
To perform IVT for production of synthetic circZNF609, the sequence of the aptamer from 
plasmids pGEM-3E5T7t was replaced by the sequence of circZNF609. For further 
analysis, several constructs were generated (Fig. 2.14 A) 
After PCR amplification of the template with necessary sequence for transcription and 
circularization, IVT was performed. The RNA was isolated and run on 6% denaturing Urea 
PAGE for 4 hours and 16 hours (overnight). However, we were not able to distinguish the 
band corresponding to circZNF609 because of several fainted bands from Urea PAGE 
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(Supplemental Fig. 5.13). Therefore, we ran the IVT RNA on denaturing MOPS agarose 
gel. EtBr staining showed 5 strong with predicted sizes (Fig. 2.14 B). Indeed, both 
constructs IVT circZNF609 and IVT circZNF609-3xFlag showed five bands corresponding 
to the full-length transcript (Fig. 2.14 B, lane 1, band 1), the linear intermediate (band 2), 
the presumed circular product (band 3) and the 5’-3’ and the 5’ half introns in the bottom 
(band 4 and 5) (Fig. 2.14 B, lane 1 and 2). As expected, the band corresponding to the 
construct circZNF609-3xFlag (Fig. 2.14 B, lane 2, band 3) was higher than its 
corresponding circZNF609 (Fig. 2.14 B, lane 1, band 3). Moreover, the negative control 
(IVT circZNF609-Del) showed one strong band representing the linear full-length transcript 
(band 1). These results encouraged us to proceed with northern blot validation. 
 
Fig. 2.14. IVT for synthetic circZNF609 production. A) Scheme of different constructs using the 
PIE methods for production of circZNF609. All constructs include SA (CUACC) and SD (GGGU) at 
the 3’ half intron and the 5’ half intron, respectively. These 9 nts are necessary for the self-splicing 
reaction. The clone circZNF609 del lacks the 5’ half-intron and serve as a negative control. B) 1% 
MOPS Agarose of 10 ng of IVT RNA (lane 1, 2, 3) was performed. Northern blot analysis was 
detected by circZNF609 probes (lane 4, 5, 6) or 5’ intron probes (lane 7, 8, 9). SA: splice acceptor, 
SD: splice donor.  
 Northern blot validation of synthetic circZNF609  2.6.3
To detect the circular products, a serial dilution of IVT RNA from 10 pg to 10 ng (10 pg, 
100 pg, 1 ng and 10 ng) was loaded on 1% MOPS Agarose gel.  At a concentration of 10 
ng RNA, we obtained the best result (Fig. 2.14 B, lane 4-6). Specifically, we observed a 
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strong signal corresponding to the circZNF609 (Fig. 2.14 B, lane 5, band 3) and 
circZNF609-3xFlag (Fig. 2.14 B, lane 6, band 3) produced from IVT circZNF609 and IVT 
circZNF609-3xFlag, respectively. Moreover, the data showed a weak signal belonging to 
circZNF609-Del (Fig. 2.14 B, lane 4, band 1).  
To confirm that we obtained the desired circRNAs, a second probe was designed to 
recognize only the 5’ intron, but does not detect circZNF609. As expected, we could only 
observe the signal of the linear full length construct and very strong signal of circZNF609-
Del (Fig. 2.14 B, lane 7-9).  
 
Fig 2.15. Northern blot for confirmation of isolated synthetic circZNF609. A) 10 ng of isolated 
circZNF609 was loaded on MOPS Agarose gel. Northern blot was performed with ZNF609 probes 
(lane 1, 2, 3) or 5’ intron probes (lane 4, 5, 6). B) RNase R digestion of isolated circZNF609 for 
confirmation the circularity of synthetic circZNF609 by northern blot.  
Since after IVT, we observed five RNA products on MOPS Agarose gel, purifying the 
desired circZNF609 from MOPS Agarose gel is necessary for further experiments. 
Therefore, the bands corresponding to the circRNAs (Fig. 2.14 B, lane 1 and 2, band 3) 
were excised from MOPS Agarose gel and the RNA was isolated. To confirm that we 
obtained the desired circZNF609, 10 ng of isolated RNAs were run on MOPS Agarose for 
further validation by northern blot. Again, both circZNF609 and 5’ intron probes were used 
to confirm the purified circRNAs (Fig. 2.15 A, lane 1-6). Furthermore, we used RNase R to 
examine the resistance of synthetic circZNF609 to exonuclease treatment. The data 
showed that synthetic circZNF609 and to some extend circZNF609-3xFlag is resistant to 
RNase R digestion (Fig. 2.15 B, lane 4 and lane 6). Finally, cDNA synthesis from isolated 
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RNAs and Sanger sequencing confirmed the circularity of our synthetic RNAs (data not 
shown).  
Taken together, these data confirmed that we could develop a system for in vitro 
generation of circZNF609. Furthermore, we also established a method to purify the 
synthetic circZNF609 with high purity and quantity. The synthetic circZNF609 could readily 
be used for further analysis.  
 In vitro translation of synthetic circZNF609 2.6.4
Having synthetic circZNF609 in hand, we next performed in vitro translation experiments 
using rabbit reticulocyte lysate. We could obtain the expression of the positive control from 
IVT GFP linear RNA (synthetic GFP) (data not shown). Of note, the synthetic GFP was 
designed to contain a Kozak sequence for enhancing the translation of mRNA and a 3' 
poly (A) tail. A 5' m7G cap was not included in the synthetic GFP.  
However, we did not observe the protein expression from neither total IVT RNA nor 
isolated synthetic circZNF609 (data not shown). As described earlier, total IVT RNA 
contains the synthetic circZNF609 and four linear processing intermediates, all of which do 
not contain neither a 5' m7G cap nor a 3' poly (A) tail. This is because there is no 5' - m7G 
cap nor a 3' poly (A) tail on a circRNA. Therefore, we propose that 5' m7G cap is not 
required for circRNA translation but maybe other modifications are needed for efficient 
translation in vitro. Further experiments should be performed to get better understanding 
about translation of synthetic circZNF609 in vitro.  
 Transfection of synthetic circZNF609 to mammalian cells 2.6.5
Since we did not obtain expression of synthetic circZNF609 in a cell-free translation 
system, analysis of synthetic circZNF609 in cells would give us some hints about 
translation of circRNA. Therefore, we transfected the synthetic circZNF609 into HEK293T 
cells. Transfection of only synthetic circZNF609 into the cells will eliminate all possible 
protein products generated from all linear processing intermediates. The cells were 
harvested 4 hours and 20 hours post transfection. Northern blot analysis showed that the 
synthetic RNAs were taken up by HEK293T cells 4 hours post transfection (Fig. 2.16 A). 
Especially, northern blot showed strong bands of synthetic circZNF609 (Fig. 2.16 B lane 4, 
5) with the same size of the positive control, which is circZNF609 expressed from 
overexpression vector (Fig. 2.16 B lane 2, 3). However, after 20 hours, we did not observe 
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the expression of circRNAs by northern blot implying that the synthetic RNAs were 
degraded by the cells (data not shown). Western blot analysis of proteins 20 hours after 
transfection did not show any signal (Fig. 2.16 B) indicating that the transfected synthetic 
circZNF609 are not translatable.  
 
Fig. 2.16. Transfection of synthetic circZNF609 into HEK293T cells. A) HEK293T was 
transfected with plasmids for overexpression of circZNF609 (lane 2, 3) and synthetic circZNF609 
(lane 4, 5). 4 hours post transfection, RNA was harvested for northern blot analysis B) 20 hours 
post transfection, HEK293T cells were harvested for western blot analysis.  
2.7 Toward understanding of circZNF609 protein function 
Even though in vitro translation and transfection of synthetic circZNF609 did not give us 
the expected result, further experiments to understand the function of circZNF609 protein 
may give us further insight into whether or not circZNF609 indeed encodes for proteins. 
 Generation of stable cell lines 2.7.1
To understand the function of proteins generated from circZNF609, the linearized form of 
the longest ORF of circZNF609 was N-terminally fused to Flag-HA. 3 stable cell lines were 
generated, including HEK293T (Fig. 2.17 A), CMT93.hCG.Luc and HCT116.hCG.Luc 
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(data not shown). These stable cell lines expressed the Flag-HA-circZfp609 ORF in an 
inducible manner upon doxycycline induction (Fig. 2. 17 A). 
 
Fig. 2.17. Analysis of the linearized circZNF609 ORF in HEK293T cells. A) Western blot of 
HEK293T cells transiently transfected with Flag-HA-circZNF609 ORF (lane 2) and the stable cell 
line HEK293T expressing Flag-HA-circZNF609 ORF (HEK293T-FH- circZNF609 ORF) upon 
doxycycline induction (lane 3, 4). B) Prediction of the NLS in the ZNF609 full-length protein. C) 
Western blot of subcellular fractionation in CMT93 cells by anti-Zfp609 antibodies. Lamin A/C and 
Tubulin were used as nuclear and cytoplasmic markers, respectively. D) Western blot of 
subcellular fraction of HEK293T-FH-circZNF609 ORF after doxycycline induction using anti-HA 
antibodies. NONO and GAPDH served as nuclear and cytoplasmic markers, respectively.  
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 Subcellular localization of circZNF609 proteins 2.7.2
Analysis of subcellular localization showed that the full-length Zfp609 (and human 
ZNF609) protein localizes exclusively to the nucleus (Fig. 2.17 C). This is expected 
because Zfp609 (and human ZNF609) contain a predicted NLS (Fig. 2.17 B) and was 
previously reported to localize to the nucleus115. On the other hand, we observed that 
linearized Flag-HA-circZNF609 ORF localizes mostly to the cytoplasm (Fig. 2.17 D). 
Indeed, circZNF609 (and circZfp609) shares 248 aa with N-terminal of its host protein 
ZNF609 (and Zfp609) and circZNF609 does not contain the predicted NLS as shown for 
ZNF609 full-length protein (Fig. 2.17 B).  
 Identification of circZNF609 interaction partners 2.7.3
To understand further the function of circZNF609 (and circZfp609), we wanted to identify 
interaction partners of circZNF609 proteins. For this purpose, an anti-Flag IP from 
HEK293T-FH-circZNF609 ORF was performed. Mass spectrometry analysis identified 
several proteins of the integrator complex as interaction partners of circZNF609 proteins 
(Fig. 2.18 A). We could further validate these interactions by Co-IP. The data showed that 
INST10 and INTS13, but not EYFP binds to Flag-HA-circZNF609 ORF (Fig. 2.18 B). This 
is interesting because Zfp609 full-length protein was previously shown to bind to the 
proteins of the integrator complex115 and therefore it is conceivable that the putative 
proteins encoded by the circZNF609 could bind some of these interactors as well. As 
circZNF609 protein localizes to the cytoplasm, binding of circZNF609 proteins to the 
integrator complex may interfere with the functions either of ZNF609 or of integrator 
complex in the nucleus. Since integrator complex plays important roles in processing of 
small nuclear RNAs (snRNAs)150, we analysed the expression of immature U1 and U2 
snRNAs in HT29-sh-circZNF609 upon doxycycline induction (Supplemental Fig. 5.16). 
However, knockdown of circZNF609 did not have any effect in the processing of snRNAs, 
at least U1 and U2 snRNAs. Further analysis is required for the understanding the 
mechanism of circZNF609 proteins’ functions.  
Taken together, we found that circZNF609 proteins localize mainly to the cytoplasm while 
full-length ZNF609 proteins localizes exclusively to the nucleus. Furthermore, mass 
spectrometry analysis identified several proteins of the integrator complex as interaction 
partners of both circZNF609 and ZNF609 proteins suggesting an interesting mode of 
circZNF609‘s function for future investigation.  
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Fig. 2.18. Identification the interaction partners of circZNF609 ORF. A) Coomassie 
staining of Flag IP of the HEK293T-FH-circZNF609 ORF with and without doxycycline 
induction. Mass spectrometry analysis identified several proteins of the integrator complex 
may potentially interact with circZNF609 ORF. B) Either EYFP or INTS10 or INTS13 (all 
Myc-Tagged) and Flag-HA-circZNF609 ORF were co-transfected into HEK 293T cells. 
FLAG-IPs were performed to validate the potential binding of circZNF609 ORF with 
INTS10 and INTS13.  
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2.8 In vitro and in vivo validation the function of circZNF609 
during colorectal cancer progression 
 In vitro proliferation assay  2.8.1
From RNAseq analysis of our mouse model, circZNF609 is upregulated in primary tumor 
as well as liver metastasis suggesting that circZNF609 may play a role in development of 
colorectal cancer. To investigate the impact of circZNF609 on colon cancer development 
in vivo, we generated different stable cell lines, including HT29-sh-circZNF609, HCT116-
sh-circZNF609 and CMT93-sh-circZfp609, which itself can produce siRNAs to knock down 
ciZNF609 upon doxycycline induction. HT29-sh-circZNF609 and HCT116-sh-circZNF609 
cell lines stably expressing shRNA targeting circZNF609 were generated using lentivirus 
(Fig. 2.19 A) while CMT93-sh-circZfp609 stable cell lines were obtained using transient 
transfection of construct described in Fig. 2.4 C.  
To confirm the expression of siRNA in an inducible manner, northern blot was performed 
three days after doxycycline induction. Northern blot revealed that the desired siRNAs 
were induced significantly upon induction with doxycycline in all cell lines (data not shown). 
Subsequently, we observed a significant knockdown of circZfp609 without affecting the 
expression of Zfp609 mRNA in CMT93-sh-circZfp609 cell line (Fig. 2.21 A). Moreover, we 
could also specifically target circZNF609 in both HT29-sh-circZNF609 and HCT116-sh-
circZNF609 polyclonal cell lines (Fig. 2.19 B, C).  
To address the effect of circZNF609 knockdown on the proliferation, XTT assays were 
performed. The data showed that knockdown of circZNF609 upon doxycycline induction 
decreases cell proliferation of both HT29-sh-circZNF609 and HCT116-sh-circZNF609 cells 
(Fig. 2.19 D, E). Further investigation by immunofluorescent (IF) analysis of HT29-sh-
circZNF609 cells four days treated with doxycycline revealed different cell behavior 
between doxycycline-treated and nontreated ones (Fig. 2.20 A). In this experiment, we 
seeded a single cell on coverslip and four days after induction, the cells were fixed and 
stained with anti--tubulin. Especially, the data showed that upon induction of doxycycline, 
the cells tend to stick together compared to the non-treated ones. This implied that the 
decrease in proliferation could be result of a defect in cell division (Fig. 2.20 A). In the 
future, it would be interesting to study the effect of circZNF609 knockdown on cell-cell 
interaction and migration in vitro.  
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Fig. 2.19. Knockdown of circZNF609 decreases cell proliferation. A) Part of lentiviral vector for 
knockdown of circZNF609 via viral transduction. B) C) Relative expression of circZNF609 and 
ZNF609 in the stable cell line HT29-sh-circZNF609 (B) and HCT116-sh-circZNF609 (C) upon 
doxycycline induction validated by qPCR. The relative expression of circZNF609 was normalized to 
the expression of GAPDH. D) E) Knockdown of circZNF609 decrease cell proliferation in HT29-sh-
circZNF609 (D) and in HCT116-sh-circZNF609 (E). Dox: Doxycycline 
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Fig. 2.20. Knockdown of circZNF609 decreases colon cancer progression and metastasis in 
vivo. A) IF of the HT29-sh-circZNF609 colony four days after induction with doxycycline. The cells 
were stained with DAPI and anti--tubulin antibodies. B) HT29-sh-circZNF609 cell lines were 
injected into spleen of the SCID mice. Spleens contain primary tumors and livers with metastases 
were imaged for macro analysis. The according tumors were resected and measured by tumor 
weight. Relative expression of circZNF609 of RNA isolated from primary tumors and liver 
metastasis by qPCR. The relative expression was normalized to ZNF609. Dox: Doxycycline.  
 In vivo xenograft mouse model 2.8.2
 HT29/SCID 2.8.2.1
Since depletion of circZNF609 in HT29-sh-circZNF609 cells upon doxycycline induction 
led to decrease in cell proliferation in vitro, we wanted to test the effect of circZNF609 
knockdown in vivo. Therefore, 500.000 HT29-sh-circZNF609 cells were injected into 
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spleen of SCID mice. Depending on the signal of luciferase, mice were sacrificed 
accordingly. The data showed that upon induction with doxycyline, less primary tumor 
development as well as less liver metastases compared to the control group was observed 
(Fig. 2.20 B). The RNA from those tumors was collected for qPCR analysis. qPCR 
analysis showed a clear decrease in the expression of circZNF609 while the expression of 
ZNF609 was not changed (Fig. 2.20 B).  
 CMT93/C57BL/6 for knockdown of circZfp609 2.8.2.2
As the phenotype obtained from our knockdown experiments could also be due to off-
target effects, we attempted to design a second siRNA to confirm our data. However, the 
second siRNA should also target the junction of the circZNF609 since this feature is 
unique to circRNA. However, designing such an siRNA which does not target its cognate 
host gene is difficult. To overcome this problem, we searched for potential off-targets of 
our siRNA within the human and mouse transcriptome. We found that the top potential 
targets of this siRNA in human and mouse are different (Table 3). Therefore, if we get the 
same phenotype of circZNF609 knockdown using human and murine cell lines, it is 
unlikely because of the off-target effects. 
Analysis of human circZNF609 and murine circZfp609, we found that the designed siRNA 
can target the murine circZfp609 as well. Therefore, we decided to validate the effect of 
circZfp609 knockdown in the murine CMT93.hCG.Luc cell lines (Fig. 2.21 A). To study the 
function of circZfp609 in vivo, 500.000 CMT93-sh-circZfp609 cells were subcutaneously 
injected into C57BL/6 mice. The data showed that upon induction with doxycycline, the 
tumors are smaller (Fig. 2.21 B, C). However, more mice are needed for statistically 
significant data. From what we observed, this in vivo data is consistent with the data 
obtained from the HT29-sh-circZNF609/SCID mouse model. 
Taken together, the result from circZNF609 knockdown using human colorectal cancer 
HT29-sh-circZNF609 cell line transplanted into SCID mice supports our cell proliferation 
experiments in vitro suggesting that circZNF609 indeed plays a role during colon cancer 
progression. Furthermore, we obtained the same data when we knocked down murine 
circZfp609 in CMT93-sh-circZfp609 cell line transplanted into C57BL/6 mice. Therefore, 
we conclude that the phenotype obtained from knockdown experiments is not because of 
off-target effects.  
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Fig. 2.21. Knockdown of circZfp609 decreases colon cancer progression. A) Relative 
expression of circZfp609 and Zfp609 in the stable cell line CMT93-sh-circZfp609 upon doxycycline 
induction validated by qPCR. The relative expression of circZfp609 was normalized to the 
expression of GAPDH. B) In vivo data of tumor resected from the mice subcutaneously injected 
with CMT93-sh-circZfp609 upon doxycycline induction. The tumor development was calculated by 
measuring the tumor weight. Dox: Doxycycline.  
 CMT93/C57BL/6 for overexpression of circZfp609 2.8.2.3
To further confirm the phenotype obtained from circZNF609 knockdown, we wanted to test 
the effect of circZNF609 overexpression in vivo. Therefore, we generated an inducible 
stable cell line CMT93.hCG.Luc expressing circZfp609 (CMT93-circZfp609) upon 
doxycycline induction (Fig. 2.12 B). As expected, the qPCR data show upregulation of 
circZfp609 upon doxycycline induction (Fig. 2.22 A).  
Next, we performed in vivo experiments by injecting 500.000 cells of the CMT93-
circZfp609 stable cell line subcutaneously into C57BL/6 mice. The data showed that upon 
induction with doxycycline, the mice developed a bigger tumor size compared to the non-
induction control (Fig. 2.22 B). Consequently, this resulted in bigger tumor volume (Fig. 
2.22 C) as well as tumor weight (Fig. 2.22 D) upon doxycycline induction. Since the data 
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obtained from overexpression experiments is opposite to the data obtained from 
knockdown experiment, this further supports our phenotype we observed from previous 
experiments.  
 
Fig. 2.22. Overexpression of circZfp609 promotes colon cancer development. A) CMT93-
circZfp609 stable cell line was induced by doxycycline for 3 days. Afterward, the cells were 
harvested for qPCR analysis. B) C) D) In vivo data from the mice overexpressing circZfp609 upon 
doxycycline induction (n=10). Induction of circZfp609 by doxycycline increases tumor volume (C) 
and tumor weight (D). Dox: Doxycyline.  
In conclusion, in vitro and in vivo experiments confirmed that circZNF609 functions as 
oncogene to promote the progression of colorectal cancer. Further experiments are 
needed to study if circZNF609 proteins have any function in colon cancer development. 
Moreover, it is not clear whether circZNF609 functions as non-coding or coding RNA. 
Therefore, it would be very interesting to investigate this aspect in the near future.  
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3 Discussion 
CircRNAs are becoming the new regulatory class of non-coding RNAs. Several studies 
have revealed that circRNAs are differentially expressed in several tissues and diseases. 
Consequently, some of circRNAs were shown to play important roles in several diseases 
such as cancer, cardiovascular disease and neurological disease. So far, the molecular 
mechanisms for most of circRNAs are related to miRNA sponges. 
In this study, we found that circZNF609 is upregulated during colorectal cancer 
progression and metastasis. In vitro and in vivo experiment implied that circZNF609 can 
function as oncogene. Interestingly, we found that circZNF609 could potentially encode for 
proteins and these proteins share the AUGs with its host mRNA, ZNF609. Using Flag 
reporter constructs and mutagenesis, we could show that the translation of circZNF609 is 
possible. Furthermore, mass spectrometry analysis identified several proteins of the 
integrator complex as interaction partners of circZNF609 proteins. We found that 
circZNF609 proteins localize to the cytoplasm whereas ZNF609 proteins localize 
exclusively to the nucleus. Since both circZNF609 and ZNF609 bind to the integrator 
complex, further analysis of these interactions would shed lights on how circZNF609 
functions.  
3.1 Overexpression of circZfp609 
Several labs attempted to overexpress circRNAs in mammalian cells. The first 
overexpression construct was produced from the Kjems lab where they used base pairing 
between the long inverted sequences of flanking intron for producing circRNA, as shown 
for ciRS-770. Furthermore, as intron pairing is a cis element for biogenesis of circRNAs, the 
Willusz lab showed that circRNAs can successfully be generated using several introns, 
including intron flanking circZKSCAN1 or circLaccase 252. Importantly, these plasmids 
were shown to be more efficient in producing circRNAs compared to the method 
developed by the Kjems lab52. Another study used the overexpression construct for 
circRNA production with its endogenous flanking intron as shown for circMbl45. Others 
used the type 1 intron self-splicing of bacteriophage T4 td gene for overexpression as 
shown for circFoxo3105. However, compared to the above methods, this is not the ideal 
method because there are extra nucleotides included in the overexpressed circRNAs 
which could be problematic for further functional studies.  
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In this study, the circZfp609 is produced using the flanking intron of circZKSCAN1, which 
was developed by the Willusz lab. Consistent with the previous conclusion52, we also 
observed that using the circZKSCAN1 intron is more efficient in producing circRNAs 
compared to methods developed by the Kjems lab70 (Fig. 2.5 B). The fidelity of 
overexpressed circZfp609 was confirmed by comparing to the expression of endogenous 
circZfp609 (Fig. 2.5 B). Further validation including Sanger sequencing and RNase R 
treatment proved that murine circZfp609 is expressed in human HEK293T cells. These 
results indicated that circZfp609 is successfully generated using chimeric circZfp609-
circZKSCAN1 intron.  
Of note, even though the overexpression of circZfp609 using the ZKSCAN1 intron worked 
very well, we still observed several linear RNA products that are produced from this 
overexpression construct (Fig. 2.5 B). This may interfere with the phenotype of circZfp609.  
Moreover, due to the longer half-lives of circRNAs compared to their linear forms, we 
observed that the stable cell lines CMT93-circZfp609 show more circRNAs than linear 
RNAs upon induction of doxycycline (Fig. 2.12 B). This is in contrast to the transiently 
expressed transcripts from the CMV promoter, where we observed more linear processing 
intermediates than circRNAs (Fig. 2.5 B). Specifically, the transient expression from CMV 
promoter was analysed one day post transfection while inducible expression by 
doxycycline was analysed three days after induction. Therefore, several linear processing 
intermediates, which were highly expressed after transcription from CMV promoter, were 
most digested after three days of induction by the cells.  
Several studies showed that circRNAs can have non-coding functions33 as scaffolds for 
RBPs104,105,108 or miRNAs151 and served as so-called ‘’sponges’’. However, one should 
keep in mind that there is precursor linear RNA generated together with circRNAs. Since 
the sequence of these precursor RNAs contain entire sequence of circRNAs, such scaffold 
or miRNA sponges should be investigated carefully to be convincing because the linear 
forms could serve as sponges as well. 
3.2 Translation of circZfp609 
It is very interesting to observe that translation of circRNA, in this case circZfp609, 
occurred in vivo in mammalian cells when fused to a 3xFlag epitope tag. We observed at 
least 3 AUGs from circZfp609 can be used to initiate the translation of circZfp609. In 
wildtype constructs, only 2 AUGs were used (Fig. 2.5 C). The third AUG was used only 
68                                                                                                                      DISCUSSION 
 
 
 
when the first AUG was mutated to ACG, much better than when the second AUG was 
mutated (Fig. 2.6 B).  
 
Fig. 3.1. Topological distance between entering ribosome and exiting ribosome on mRNA 
and circRNA. A) On mRNA, the binding of eIF4E, eIF4G and PABP forms a highly stable, a 
closed-loop structure of circular mRNA–protein complex152,153. Even though there is existence of a 
circle structure, ribosome enters at a 5’ cap and exits near the polyA tail in a far topological 
distance. B) On circRNA, such initiation proteins are not yet known. However, the entering 
ribosome and exiting ribosome are presumably happened at very close topological distance.  
As suggested in the introduction (see 1.4.2), in a circRNA, the beginning of the ORF is 
topologically close to the end of the ORF (Fig. 3.1). This means that initiation and 
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termination will presumably occur in close proximity and the two processes might positively 
or negatively influence each other. This could explain why we only observed the usage of 
the third AUG when the first AUG is mutated (Fig. 2.6 B). Moreover, we observed the 
usage of all 3 AUGs from circZfp609 when we lengthened the UTR of circZfp609 by 
adding 49 nts unrelated sequence (in this case the -globin 5’ UTR) just in front of the first 
AUG. Adding these 49 nts might increase the proximity between initiation and termination 
and therefore, the third AUG was used for translation. 
Because cellular mRNAs have a m7G cap at the 5’ end of mRNA, the translation of these 
RNAs are followed the cap-dependent scanning mechanism152. However, when the cap-
dependent scanning initiation is inhibited, some cellular mRNAs can alternatively be 
translated by cap-independent mechanisms, for examples initiation via IRES154. Since 
circRNAs do not contain m7G cap, translation on circRNAs is supposedly initiated through 
cap-independent mechanism mediated by IRES sequence. However, we did not observe 
IRES sequence as described for other circRNAs, such as circMbl or circFBXW7, on 
circZfp609. As IRES determines the sites where the ribosomes enter to the circles, we 
speculate that on circZfp609, the ribosomes can initiate translation of the circRNA-
embedded ORF at several place. This is consistent with our observation that several 
AUGs, at least seven AUGs, can be used for initiation of circZfp609. Indeed, we observed 
that four AUGs from the exogenous sequence, in this case 3xFlag tag, can be used for 
initiation of translation suggesting that adding some sequence can affects circRNA 
translation. Such observation was reported previously that the Flag sequence itself can 
drive translation without any specific IRES96. Taken this evidence together, we suggest 
that the scanning mechanism of mRNA translation is not applicable to circZfp609, and 
potentially even other circRNAs.  
In theory, ribosomes can go around the circle several times, if it is not properly terminated. 
It has been observed for an infinite GFP ORF94, ribosomes can ‘’travel’’ several times, 
more than 10 times. As mentioned in the result, we observed that in our circZfp609 
construct Del121-AU, the four AUGs from 3xFlag tag can be used for translation initiation 
giving four ORFs with the longest ORF is 873 nts (Fig 2.11 D). However, the Del121-AU 
circZfp609 mutant is a 820 nts circRNA suggesting that ribosomes traveled 1,065 
(873/820) times of the circle (Fig 2.11 D). Therefore, we proposed (at least for circZfp609) 
that the ribosomes can recognize and initiate translation from several AUGs and can travel 
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on a circRNA more than one circle. Such rolling circle translation was previously reported 
in both prokaryote and eukaryote95,96.  
How ribosomes can be recycled on a circRNA? In bacteria, after completing translation, 
the ribosomes are disassembled for the next round of translation through the recycling 
process155,156. Moreover, several studies proposed that the ribosome recycling factor 
(RRF), elongation factor (EF-G) and initiation factor IF3 are involved recycling in 
prokaryotes157. Even though recycling of ribosomes has been well studied for mRNA in 
prokaryotes, the RRF homologue has not been found in eukaryotes suggesting that the 
recycling may require different factors158. Indeed, it was shown that initiation factors eIF3, 
eIF1, eIF1A158 and ABCE1159,160,161 can promote recycling of eukaryotic ribosomes. Since 
ribosomes can translate several times on a circle, for example, on the mentioned infinite 
GFP ORF94 , it is not clear whether or not ribosomes are disassembled on a circRNA (Fig. 
3.1). Moreover, if ribosomes are recycled, do they use the same factors as mRNA? In 
some cases, after termination, ribosomes do not undergo complete recycling and 
reinitiation was observed162,163. Therefore, in the future, it is interesting to examine if 
ribosomes reinitiate a new round of translation without recycling on a circRNA.  
3.3 CircRNA synthesis in vitro 
During the course of this study, several efforts have been made to generate synthetic 
circRNAs in vitro. One of the approaches used ligation of transcribed RNA. It works very 
well for several small circRNAs but it is more challenging for long circRNAs (unpublished 
data from the Meister lab). Moreover, circRNAs have slower mobility comparing to the 
linear RNAs with the same sizes on Urea PAGE. At first, we tried to run circZNF609 on 
Urea PAGE gel with percentage ranging from 4-6%. However, we could not obtain good 
resolution for circZNF609 (Supplemental Fig. 5.13). Moreover, the yield of circZfp609 we 
could get from UREA PAGE was very low. Another problem is that the running mobility of 
circRNA on MOPS Agarose gel is different from Urea PAGE. Specifically, circRNAs have 
the same mobility with linear RNA at the same sizes on MOPS Agarose. Therefore, such a 
ligation-based approach is not distinguishable on MOPS Agarose gel.  
Later on, we switched to in vitro self-splicing group I introns from genes coding for 
thymidylate synthase (td) of bacteriophage T4 164,165 using PIE methods149,166,167,148. This is 
effective method for producing circRNAs and was recently reported in several 
studies111,148. However, the splice sites from Td gene of bacteria, which contains 4 nts at 
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the 3’ intron and 5 nts at the 5’ intron, are necessary for producing circRNAs148. Therefore, 
the resulting synthetic circRNAs contains 9nts from the intron. Such extra nts should be 
taken into account because of several reasons. First, the junction of circRNAs is the 
unique sequence that distinguishes circRNAs from their cognate mRNAs. We would 
speculate that the junction of circRNAs may contain binding sites for miRNAs or RBPs, 
which are different from their host mRNAs. When engineering such synthetic circRNA 
using in vitro self-splicing, adding 9 nts extra to the junction of circRNA may disrupt these 
sites. Secondly, adding 9nts may change secondary structure of circRNAs. Since 
circRNAs are considered as non-coding RNAs, such changes may affect binding to other 
miRNAs or RBPs and eventually their function. Thirdly, transfecting circRNAs generated 
by in vitro self-splicing could stimulate innate immune response as shown recently111.  
3.4 Transfection of circRNAs into mammalian cells 
Northern blot revealed that circZNF609 is taken up from HEK293T cells 4 hours post 
transfection. After 20 hours, circRNAs were mostly degraded. Such degradation pathways 
of circRNAs are not yet reported and it is interesting to understand which nucleases, 
presumably endonucleases, degrade these circRNAs.  
To investigate the translation potential of transfected synthetic circZNF609, western blot 
was performed with HEK293T cells 20 hours post transfection. However, we did not 
observe any band belonging to the expected proteins. There are several reasons which 
can explain this result. First, synthetic circZNF609 may change its secondary structure. 
This may affect its potential to recruit ribosomes for translation. Second, the translation 
mechanism of circRNAs is not yet characterized and the synthetic circZNF609 itself may 
not fulfill all requirements for protein translation in mammalian cells. For examples, one 
study suggested that m6A is important for translation of a subset of circRNAs. Indeed, 
m6A promote initiation of protein translation from circRNAs in human cells by recruiting 
initiation factor eIF4G2 and m6A reader YTHDF384. If it is also true for circZNF609, it 
should be m6A methylated in vitro before transfecting to the cells so that ribosomes can be 
recruited afterwards. Third, synthetic circZNF609 was already degraded 20 hours post 
transfection. This means that the cells recognize the synthetic circZNF609 as unwanted 
products and transfer those products immediately to the degradation pathway.  
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3.5 Effect of circZNF609 on colorectal cancer progression in 
vitro and in vivo 
As shown by MTT, cells grew slower when we knocked down circZNF609 upon 
doxycycline induction. Of note, doxycycline does not give any effect to the cells because 
treatment of doxycycline to HCT116 cell does not lead to any changes in cell growth 
(Supplemental Fig. 5.15). Since only one siRNA was used in this experiment, the observed 
phenotype could still be an off-target effect. However, as siRNA targeting circRNA is 
designed only at the junction of circRNAs, there are not many choices for designing such 
siRNAs. One solution would be moving the siRNA a few nts way from each other. 
However, in any case, the siRNA should not target the cognate mRNAs.  
Since this siRNA targets both human circZNF609 and murine circZfp609, we searched for 
potential off-targets in the human and mouse transcriptomes. We observed that this siRNA 
target different transcripts in human and mouse. Moreover, the in vivo data observed from 
HT29/SCID and CMT93/C57BL/6 mouse model gave us the similar phenotype. Since it is 
unlikely that different off-targets lead to the same phenotype, this could strengthen our 
data about the on-target effects of circZNF609 knockdown on tumor development.  
To further support our data, we generated the stable cell line CMT93-circZfp609 for 
overexpression of circZfp609 upon doxycycline induction. In this case, we observed an 
increase in tumor development in vivo. This is consistent with the RNAseq data from our 
mouse model, which showed that circZfp609 is upregulated in primary tumor and liver 
metastasis. Thus, the data from circZfp609 overexpression was opposite to the data 
obtained from circZfp609 knockdown, confirming the potential roles of circZfp609 in tumor 
progression.  
Even though these data sets are convincing, the rescue experiments are necessary to fully 
support our data. However, such rescue experiments are rather difficult and tricky. We 
have tried to rescue the phenotype of circZfp609 knockdown but several things should be 
taken into account. First, we do not know if the function of circZfp609 is from its non-
coding or coding potential. Evidence from our data suggests that circZfp609 may encode 
for proteins using overexpression constructs. However, we do not know if the proteins from 
circZfp609 are produced or if produced, are really abundant in the cells. If circZfp609 
encodes for proteins, the designing of resistant construct for rescue experiment is 
straightforward by following the silent mutation rules. However, if circZfp609 does not 
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encode for protein and function as non-coding RNA, the design of the resistant construct 
should follow other rules to maintain the structure, and therefore the function, of 
circZfp609.  
To overcome this, we tried to identify the cis sequence in the endogenous intron of 
circZNF609 that re important for biogenesis of circZNF609. If we could do so, we would be 
able to target circZNF609 by CRISPR/Cas9. We cloned the endogenous circZNF609 and 
recapitulated the expression of circZNF609 from its intron in vitro. However, we did not 
observe the circZNF609 generated from this construct (Supplemental Fig 5.10). Further 
analysis is necessary to understand how circZNF609 is generated from its endogenous 
locus.  
3.6 Potential function of circZNF609 as miRNA sponges 
Since a few circRNAs are well-known to function as miRNA sponges, circZNF609 were 
proposed to sponge 2 miRNAs: miR-615-5p and miR-150-5p in 2 different studies118,119. 
However, we would believe that such miRNA sponge situation may not happen widely in 
nature, not only for circZNF609 but also for many other circRNAs. This was suggested 
earlier by the fact that most circRNAs are low abundant69. Moreover, from the deep 
sequencing analysis, the expression of the miRNAs: miR-615-5p (Supplemental Fig. 5.6) 
and miR-150-5p in HT29 (Supplemental Fig. 5.7) is very low (less than 10 reads per 
million reads) and such low expression of miRNA may not be enough to function as 
miRNA sponges, at least in HT29 cells. We, therefore, believe that circZNF609 does not 
sponge the suggested miRNA in HT29 or at least such interaction would not be 
functionally relevant. We would speculate that if it happens, circZNF609 may sponge other 
miRNAs.  
3.7 Analysis of proteins generated from circZNF609 
Without any tag in overexpression constructs, we observed several protein products 
recognized by anti-Zfp609 antibodies apart from other nonspecific bands. In the stable cell 
line CMT93-circZfp609, we observed more than 2 protein products, some of which do not 
have corresponding protein bands in non-induction CMT93-circZfp609 cell line (Fig. 2.14 
A). This could be explained by the fact that there are several proteins produced from the 
circRNA overexpression construct.  
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Indeed, we observed that several linear RNAs generated from circRNA overexpression 
constructs apart from the desired circRNAs. First, due to incorporation of strong bGH poly 
(A) stop signal at the end of the transcript, we could rule out the production of concatamer 
as discussed before (Fig. 2.7). However, there were at least 2 transcripts generated in this 
case: the linear precursor RNAs containing upstream intron-circularized exon-downstream 
intron and the circRNAs. Since the precursor RNAs contain the circularized exon with 
exact sequence of circZfp609, this could positively or negatively interfere with the function 
of circZfp609. For examples, in the overexpressed constructs, if we put the 3xFlag 
sequence after the first AUG of circZfp609, we observed 2 proteins products produced: 
one from the circRNA and other one from the linear precusor RNA (Fig. 2.12 D). In this 
case, we need to be very careful when analyzing the phenotype caused by any of these 
proteins or both.  
3.8 Interaction partners of circZNF609 proteins 
Identification the interaction partners of circZNF609 proteins gives us some hints about the 
function of circZNF609. Mass spectrometry analysis identified several proteins which 
belong to the integrator complex, including INTS10, INTS13, INTS14. Interestingly, 
integrator proteins were recently reported to interact with Zfp609 full-length protein to 
regulate gene expression115. Cellular fractionation revealed that the full-length Zfp609 
localizes exclusively to the nucleus. Of note, the predicted NLS of Zfp609 is not present in 
the circularized exon of circZfp609. Consistently, we observed that the overexpressed 
linearized circZfp609 protein fused to Flag-HA localizes mainly to the cytoplasm. 
If circZfp609 encodes for proteins, this cytoplasmic-localized proteins would interfere with 
the function of the full-length protein Zfp609. However, in this case, this also implies that 
Zfp609 protein may have function in colorectal cancer. This is not elucidated so far. 
Moreover, integrator complex proteins were reported to have additional function in the 
cytoplasm168. Therefore, the binding of circZfp609 to integrator complex proteins may 
function independently from Zfp609 proteins. Of note, integrator proteins are well-known 
for their function in snRNA biogenesis150,169. We checked the processing of snRNAs in 
case of circZNF609 knockdown but we have not observed any defect in biogenesis of 
snRNAs. Therefore, circZNF609 may have other functions than snRNA biogenesis. For 
examples, circZNF609 may sequester the integrator proteins to the cytoplasm and 
interfere other functions of integrator complex.  
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In case that circZNF609 does not encode for proteins and function as non-coding RNA, 
the interaction of the linearized part of circZNF609 and integrator proteins could also be 
explained. We would speculate that circZNF609 contains a protein part of full-length 
ZNF609, this part would serve as the domain for binding to integrator proteins. 
Overexpression of this truncated protein fragment from ZNF609 results in identification of 
integrator proteins from mass spectrometry data. This overexpression could give some 
‘’dominant-negative effect’’ to the cells because it localizes to the cytoplasm. Such 
hypothesis should be investigated further in the future. So far, the endogenous circZNF609 
protein has not been found. Maybe circZNF609 protein are low abundant and thefore a 
relevant function of such low abundant protein is questionable. Further analysis using 
mass spectrometry analysis would be necessary to address this issue.  
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4 Outlook 
There is still a long road ahead until the role of circZNF609 on colorectal cancer 
progression and metastasis becomes clear. Currently, we are performing cell proliferation, 
cell migration and cell invasion to understand the functions of circZNF609 and/or the 
proteins generated from circZNF609 in vitro. We are also performing xenograft mouse 
experiment of CMT93-Flag-HA-circZfp609 ORF transplanted into C57BL/6 to figure out the 
relevant function of circZNF609 in vivo. It is also interesting to understand if the full-length 
ZNF609 has any roles in colorectal cancer development. In this study, we found that both 
ZNF609 and circZNF609 proteins bind to some proteins of the integrator complex. In the 
future, it would be necessary to examine further this interaction in the context of colorectal 
cancer metastasis.  
The mechanisms of how circRNAs can recruit ribosomes are not clear. At the moment, 
there are just only a few publications showing that circRNAs can encode for proteins84,86,87, 
88. Further experiments to identify initiation factors that recruit ribosomes for translation 
would help to understand circRNA translation mechanisms. In this work, we found that 
several AUGs can be used to initiate translation of circZfp609. It would be interesting to 
understand how AUGs can be selected for translation and how scanning mechanism 
works on circRNA in the future.  
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Supplemental Fig. 5.1. Mouse preparation for development of primary tumor and liver metastasis.  
A) Mouse weight (g) was measured every day 7 days after injection of HT29.hCG.Luc cells to the 
spleen. B) In vivo bioluminescence monitoring of intrasplenic HT29.hCG.Luc tumors. 3-7 days after 
injection, primary tumors developed. For bioluminescence imaging, mice were intraperitoneally 
injected with 150 mg/kg of luciferin and imaged weekly. All mice were sacrificed when 
bioluminescence levels reached about 500.000 photons/s (about 4 weeks after injection). 
 
 
Supplemental Fig. 5.2. Information regarding to the deep sequencing of rRNA-depleted 
transcriptome library 
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Supplemental Fig. 5.3. Principle component analysis (PCA) of all miRNA libraries prepared for 
deep sequencing from our mouse model. PT: primary tumors, LM: Liver metastasis.  
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Supplemental Fig. 5.4. Distance plot of all miRNA libraries prepared for deep sequencing from 
our mouse model. PT: primary tumors, LM: Liver metastasis. 
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Supplemental Fig. 5.5. Heatmap of top 50 most variant miRNAs from deep sequencing data. PT: 
primary tumors, LM: Liver metastasis  
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Supplemental Fig. 5.6 Expression of miR-615-5p in HT29 cells (HT), primary tumors (PT) and 
liver metastasis (LM) 
 
Supplemental Fig. 5.7. Expression of miR-150-5p in HT29 cells (HT), primary tumors (PT) and 
liver metastasis (LM) 
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Supplemental Fig. 5.8. Differential expression of miRNAs and mRNAs during primary tumor 
development in the HT29.hCG.Luc/SCID mouse model. A) Scatter plot of differential expression of 
miRNAs between HT29.hCG.Luc cell lines and primary tumors. A threshold cutoff of 20 reads per 
million mapped reads was set for fold change analyses. RPM: reads per million mapped reads. B) 
Scatter plot of differential expression of the transcriptome between HT29.hCG.Luc cell lines and 
primary tumors. All significant mRNAs and lncRNAs are shown. FPKM: fragments per kilobase of 
exon model per million mapped fragments. 
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Supplemental Fig. 5.9. Characterization of circZNF609. A) Northern blot of the fractionated 
polyA (+/-) RNA from HT29 cells. 20 ug of Total RNA or polyA (-) RNA and 2.5 ug of polyA (+) RNA 
was loaded on 1% MOPS Agarose gel. Northern blot using probes detected both ZNF609 and 
circZNF609 was performed. Northern blot analysis showed that circZNF609 is not enriched in the 
polyA (+) fraction as shown by ZNF609. We detected circZNF609 in both Total RNA or polyA(-) 
RNA fraction. B)  Serum of the SCID mice injected with HCT116.hCG.Luc cells was collected at 
the time of scarification (around 4 weeks after injection). Relative expression using qPCR primer 
for circZNF609 showed the abundance of its expression in serum normalized to GAPDH. Notably, 
linear RNAs including GAPDH and ZNF609 are not stable in the serum. Since circZNF609 is highly 
conserved, the qPCR could presumably detect the murine circZfp609. C) Alignment of the 
sequence of the amplicon of circZNF609 and circZfp609 that amplified by qPCR primer. Since 
there are mismatches between human circZNF609 and murine circZfp609, deep sequencing 
showed that 0,84 % of the amplicon belongs to human circZNF609. This implied that the human 
circZNF609 is secreted to the serum of the SCID mice and potentially served as future promising 
biomarkers. D) Alignment of the aa sequence of human circZNF609 (HS) and murine circZfp609 
(MMU). 
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Supplemental Fig. 5.10. Analysis of circZNF609 produced from its endogenous locus. A) 
Snapshot of the UCSC genome browser of the circZNF609 locus. Here, it was annotated that 
circZNF609 is generated from exon 1 of human ZNF609. However, from our RNAseq analysis, 
circZNF609 comes from exon 2 of ZNF609. circZNF609 was previously identified from several 
studies27,26,65. PCR amplifying 4 kb upstream intron, circZNF609 exon and 3 kb downstream intron 
was performed. Endo-circZNF609 was generated by assembly these fragments by SLIC cloning. 
The full fragment was then cloned into the pcDNA3.1 (+) vector. B) HEK293T was transfected with 
different constructs for expressing circZNF609. 2 days post-transfection, the RNA was harvested 
for northern blot analysis. Northern blot showed the strong expression of the positive control, 
circZNF609 expression form ZK-circZNF609 vector. However, the endo-circZNF609 showed no 
signal of circZNF609.  
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Supplemental Fig. 5.11. Further mutagenesis of Zfp609 5’ UTR for studying its translation 
mechanism. A) Truncated mutants of circZfp609 5’ UTR. C) Northern blot of HEK293T cells 
transfected with all 5’ UTR deletion mutants showed expression of overexpressed circZfp609 5’ 
UTR mutants. D) Western blot of samples from C) with anti-Flag antibodies. Several mutants were 
shown in Fig. 2.9. Only Del 90-121 was included in this western blot. The data show that Del 90-
121 gives us no protein expression recognized by anti-Flag antibodies. 
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Supplemental Fig. 5.12. Further mutagenesis of Zfp609 UTR for studying its translation 
mechanism (continued). A) Truncated mutants of circZfp609 5’ UTR were generated to understand 
how circZfp609 can recruit the ribosome. 1x Flag without any AUG in its sequence was inserted 
just before the stop codon (ZK-circZfp609-1xFlag No AUG). 1x HA was inserted into the circ-
Zfp609-3x Flag just after the first AUG (ZK-circZfp609-3xFlag-1xHA at 1st AUG) or second AUG 
(ZK-circZfp609-3xFlag-1xHA at 2nd AUG). 10 unrelated nts were added to the Del 121 construct. B) 
Western blot of the HEK293T cells transfected with different mutants by anti-Flag antibodies. ZK-
circZfp609-1xFlag No AUG gave no protein band. This implied that 3xFlag is better for recognition 
by anti-Flag Antibodies. ZK-circZfp609-3xFlag-1xHA at 1st AUG give 2 protein products. 
Surprisingly, ZK-circZfp609-3xFlag-1xHA at 2nd AUG gave only one bigger protein products. The 
second protein products were not detected by anti-Flag antibodies. As discussed, potential AUG in 
HA was removed but unexpectedly, one stop codon in the HA sequence could potentially use from 
upstream AUG resulting one complete ORF. We speculated that this ORF was used and therefore 
the second AUG of Zfp609 was not used for translation. Further analysis should be performed to 
get a final conclusion about these mutants. Del 121 gave lower protein products from second AUG. 
However, Del 121+UCCGGCGGAA gave similar protein products as Del 121-AU. 
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Supplemental Fig. 5.13. IVT for synthetic circZNF609 production on Urea PAGE. A) Scheme of 
constructs using the PIE methods for production of circZNF609. circZNF609-SS was generated by 
deleting 9 splice sites necessary for in vitro self-splicing reaction by quick change mutagenesis. 
The RNA was isolated after IVT reaction using TRIzol-LS reaction. RNA was run on 6% Urea 
PAGE for 4 or 20 hours.  
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Supplemental Fig. 5.14.  Fidelity of the synthetic circZNF609 by PIE method. A) Scheme of PCR 
oligos for amplification of synthetic circZNF609. B) The RNA was isolated after IVT and ran on 1% 
MOPS Agarose. The data showed that circZNF609-SS RNAs are generated from self-splicing 
using PIE method. C) 1 ng of the isolated RNA from MOPS Agarose gel was used for cDNA 
synthesis. PCR of the indicated oligos was performed. The PCR products were run on 1% Agarose 
gel. D) Isolated PCR products were then cloned into a pGEMT-easy vector. Sanger sequencing 
showed that the RNA obtained from circZNF609-SS lacks 8 nts of the circZNF609 junction.  
 
Supplemental Fig. 5.15. Doxycycline does not have any effect on the proliferation of HCT116 
cells.  
 
 
 
 
 
 
94                                                                                                                          APPENDIX 
 
 
 
 
Supplemental Fig. 5.16. Knocking down of circZNF609 does not have effect in the processing of 
U1 and U2 snRNAs. HT29-sh-circZNF609 cells were induced with doxycycline for 3 days. After 
that, RNA was collected for northern blot and qPCR analysis. Northern blot analysis showed no 
changes in the expression of premature U1, U2 and U4 snRNAs (data not shown). qPCR was then 
used to quantitatively calculate the changes in the immature U1 and U2 snRNAs. Comparing to the 
non-induced HT29-sh-circZNF609 cells, knocking down of circZNF609 gave very small effect to 
the expression of premature U1 and U2 snRNAs.  
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Supplemental Fig. 5.17.  Method for inducible overexpression of circRNA. A) Scheme of vector 
for inducible overexpression of circRNAs. B) HEK293T was transfected with vector consecutively 
expressing circZfp609 (CMV-ZK-circZfp609) or vector for inducible expression of circZfp609 (TRE-
ZK-circZfp609). 2 days post-transfection, RNA was isolated for northern blot analysis. Northern blot 
showed expected expression of circZfp609 upon doxycycline induction. C) The same experiment 
was performed with the vector for overexpression of circGFP.  
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Table 1. List of abbreviations 
aa  amino acid 
AEBSF  4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride 
Ago  Argonaute 
Amp  ampicillin 
APS ammonium persulphate 
ATP adenosine triphosphate 
bp  base pair(s) 
BSA  bovine serum albumin 
ceRNA competing endogenous RNA 
cDNA  complementary DNA 
CoIP  co-immunoprecipitation 
circRNA circular RNA 
CRISPR Clustered Regularly Interspaced Short Palindromic Repeats 
DAPI 4’,6-diamidino-2-phenylindole 
DMEM  Dulbecco’s Modified Eagle Medium 
DANN  deoxyribonucleic acid 
dNTP  deoxynucleoside triphosphate 
Dox Doxycycline 
ds double-stranded 
DTT dithiothreitol 
EDC  1-ethyl-3-(3-dimethyl-aminopropyl)-carbodiimid 
EDTA  ethylenediaminetetraacetic acid 
eIF  eukaryotic initiation factor 
EtBr ethidium bromide 
Fig. Figure 
FBS  fetal bovie serum 
FPKM fragments per kilobase of exon model per million 
GAPDH  glyceraldehyde 3-phosphate dehydrogenase 
GDP  guanosine diphosphate 
GTP  guanosine triphosphate 
hCG Human chorionic gonadotropin 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
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HygB Hygromycin B 
IPTG  isopropyl _-D-1-thiogalactopyranoside 
IRES  internal ribosome entry site 
IVT in vitro transcription 
kDa kilodalton 
LM Liver metastasis 
Luc Luciferase 
m6A  N6-methyladenosine 
M  molar 
MCS  multiple cloning site 
min  minute 
miRNA  microRNA 
RNP  ribonucleoprotein 
mRNA  messenger RNA 
NLS  nuclear export signal 
nt (s) nucleotides(s) 
ORF  open reading frame 
PAGE  polyacrylamide gel electrophoresis 
PCR  polymerase chain reaction 
PIE permuted intron-exon 
pri-miRNA  primary miRNA 
PT Primary tumor 
RISC RNA-induced silencing complex 
RNA  ribonucleic acid 
RNP  ribonucleoprotein 
RPM reads per million 
RT  room temperature 
SA splice aceptor 
SCID severe combined immunodeficiency 
SD splice donor 
sec  second 
shRNA  short hairpin RNA 
siRNA  small interfering RNA 
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SDS  sodium dodecyl sulfate 
SSC  saline-sodium citrate bu.er 
TBE  Tris/Borate/EDTA buffer 
TBS  Tris buffered saline 
TBS(-T)  Tris-buffered saline (containing Tween 20) 
TEMED  tetramethylethylenediamine 
UTP  uridine triphosphate 
UTR  untranslated region 
XTT 
2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2H-Tetrazolium-5-
Carboxanilide 
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Table 2. circRNAs were reported to function as miRNA sponges. 
No. 
Name of the 
circRNA 
miRNA 
sponge 
Target 
Tissue relevant or 
Diseasea 
Refs 
1 HRCR miR-223 ARC heart 170 
2 
CircRNA-
CER 
MiR-136 MMP13 osteoarthritis 171 
3 CircHIPK3 miR-124 
IL6R and 
DLX2 
Human cell growth 62 
4 
CircRNA_00
1569 
miR-145 
E2F5, BAG4 
and FMNL2 
Colorectal cancer 172 
5 
Hsa_circ_00
05075 
miR-23b-5p, 
miR-93-3p, 
miR-581, 
miR-23a-5p 
Several HCC 173 
6 
CircRNA 
MYLK 
miRNA-29a-
3p 
DNMT3B, 
VEGFA and 
ITGB1 
bladder 174 
7 CircTCF25 
miR-103a-
3p/miR-107 
CDK6 bladder 175 
8 CircRar1 miR-671 
Caspase8 
and p38 
Express in hippocampus 
and cerebral cortex 
Neurotoxicity 
176 
9 CircZNF609 miR-150-5p AKT3 Hirschsprung disease 118 
10 CircPVT1 
miR-125 
family 
 Gastric cancer 177 
11 Circ100284 miR-217 EZH2 
arsenite-induced cell 
cycle, express in 
keratinocytes 
178 
12 
CircRNA_00
0203 
miR-26b-5p Col1a2, CTGF 
mouse cardiac 
fibroblasts 
179 
13 CircHIAT1 
miR-195-
5p/29a-
3p/29c-3p 
CDC42 
clear cell renal cell 
carcinoma 
180 
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14 CircCCDC66 
miR-33b, 
miR-93 
MYC Colon Cancer 181 
15 
Hsa_circ_00
05105 
miR-26a NAMPT Osteoarthritis 182 
16 
CircRNA_10
0290 
miR-29b CDK6 oral cancer 183 
17 
CircRNA_01
0567 
miR-141 TGF-β1 myocardial fibrosis 184 
18 MFACR miR-652-3p MTP18 cardiomyocyte death  
19 CircMTO1 microRNA-9 p21 HCC 185 
20 
Hsa_circ_00
10729 
miR-186 HIF-1α vascular endothelial cell 186 
21 
CircRNA_10
0269 
miR-630 no gastric cancer 187 
22 MYLK miR-29a 
VEGFA/VEGF
R2 
bladder 188 
23 
CircRNA_00
0839. 
miR-200b RhoA 
hepatocellular 
carcinoma 
189 
24 
Hsa_circ_00
20397 
miR-138 
TERT and  
PD-L1 
colorectal cancer 190 
25 
CircRNA_10
0338 
miR-141-3p no  191 
26 CircABCB10 miR-1271 no Breast cancer 192 
27 
Hsa_circ_00
45714 
miR-193b IGF1R osteoarthritis 193 
28 CircLARP4 miR-424-5p LATS1 Gastric cancer 194 
29 
hsa_circ_000
1982 
miR-143 no Breast Cancer 195 
30 9 circRNAs 
miR-130a-
3p 
TRPM3 coronary artery disease 196 
31 UBAP2 miR-143 Bcl-2 osteosarcoma 197 
32 
CircRNA_00
46367 
miR-34a PPARα Hepatic steatosis 198 
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33 CircGFRA1 miR-34a GFRA1 breast cancer 199 
34 
Mmu_circRN
A_007893 
mmu-miR- 
485-5p 
IL-6 macrophages 200 
35 CircWDR77 miR-124 FGF-2 
vascular smooth muscle 
cells 
201 
36 CircFUT10 miR-133a 
MyoD, MyoG 
and MyhC 
myoblasts 202 
37 CircLMO7 
miR-378a-
3p 
HDAC4 myoblasts differentiation 203 
38 CircBIRC6 
miR-34a, 
and miR-
145 
several 
undifferentiated human 
embryonic stem cells 
204 
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Table 3. Potential human targets of circZNF609 siRNA (from 
https://blast.ncbi.nlm.nih.gov/Blast.cgi) 
Potential human targets Potential mouse targets 
• UBE2V1 
• ZNF609 
• GLB1L2 
• CAMTA1 
• FNAR1 
• LOC105370456 
• FARSB 
• Zfp609 
• Lvrn 
• Slc16a1 
• GM30771 
• Phf21a 
• Dmd 
• Hus1 
• Cdc42 
• Hipk1 
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Table 4. Top 50 proteins identified from Mass spec analysis of Flag IP from 
HEK293T-circZNF609 ORF upon doxycycline induction.  
No. 
Protein 
name 
Accession Scores #Peptides 
SC 
[%] 
1 INTS13 sp|Q9NVM9|ASUN_HUMAN 5071.7  76 70,3 
2 INTS10 sp|Q96SY0|VWA9_HUMAN 3677.9 46 77,4 
3 ZNF609 tr|A5PKW6|A5PKW6_HUMAN 3426.7  39 61,9 
4 INTS14 tr|H3BRY6|H3BRY6_HUMAN 3087.5  39 72,2 
5 HEL-S-89 tr|V9HWB4|V9HWB4_HUMAN 3059.3 40 42,5 
6 PPM1B sp|O75688|PPM1B_HUMAN 2903.3  35 67,8 
7 KIF11 sp|P52732|KIF11_HUMAN 2731.6  48 45,2 
8 TUBB tr|Q5SU16|Q5SU16_HUMAN 2528.9  40 65,8 
9 TUBB4B sp|P68371|TBB4B_HUMAN 2428.7 40 65,6 
10 STK38 tr|A0A024RD18|A0A024RD18_HUMAN 2340.7 36 57,2 
11 STK38L sp|Q9Y2H1|ST38L_HUMAN 2127.5 31 58,2 
12 WDR77 tr|A0A024R0H7|A0A024R0H7_HUMAN 2119.3  29 68,1 
13 TUBB4A sp|P04350|TBB4A_HUMAN 2100.6  35 61,9 
14 INTS10 sp|Q9NVR2|INT10_HUMAN 1935.5 37 45,6 
15 KCTD5 sp|Q9NXV2|KCTD5_HUMAN 1818.3 20 69,7 
16 N/A tr|B2RBD5|B2RBD5_HUMAN 1676.2  26 29,8 
17 C11orf84 sp|Q9BUA3|CK084_HUMAN 1479.5 19 66,9 
18 N/A tr|B3KPS3|B3KPS3_HUMAN 1428.7 21 57,2 
19 KCTD17 sp|Q8N5Z5|KCD17_HUMAN 1361.1 19 52,6 
20 HEL-S-72p tr|V9HW22|V9HW22_HUMAN 1330.8  28 37,2 
21 MAP3K7IP1  tr|A8K6K3|A8K6K3_HUMAN 1313.1  25 65,3 
22 KCTD2 sp|Q14681|KCTD2_HUMAN 1288.8  15 48,7 
23 UNC84B tr|A0A024R1P7|A0A024R1P7_HUMAN 1287.3 23 48,5 
24 TUBA1C sp|Q9BQE3|TBA1C_HUMAN 1276.6  20 54,3 
25 C7orf26 sp|Q96N11|CG026_HUMAN 1035.4  12 31,6 
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26 RIOK1 sp|Q9BRS2|RIOK1_HUMAN 986.0  21 28,5 
27 FLJ51907 tr|B7Z4V2|B7Z4V2_HUMAN 985.5 19 29,0 
28 N/A tr|A0A140VJQ4|A0A140VJQ4_HUMAN 920.2  16 44,2 
29 PABPC1 tr|A0A024R9C1|A0A024R9C1_HUMAN 892.2  19 32,5 
30 EIF4B sp|P23588|IF4B_HUMAN 803.6  12 31,9 
31 CLNS1A sp|P54105|ICLN_HUMAN 784.7  12 51,1 
32 PRMT5 sp|O14744|ANM5_HUMAN 777.1  16 25,3 
33 DHX9 sp|Q08211|DHX9_HUMAN 766.1  18 17,7 
34 TRIM21 sp|P19474|RO52_HUMAN 759.1  16 32,2 
35 FLJ35376  tr|B3KS36|B3KS36_HUMAN 753.1  13 25,4 
36 N/A tr|Q5U0D0|Q5U0D0_HUMAN 751.6 18 31,6 
37 INTS13 tr|F8VRX9|F8VRX9_HUMAN 745.4  11 73,4 
38 PRPF31 tr|F1T0A5|F1T0A5_HUMAN 718.8 13 34,7 
39 PRMT1 tr|E9PKG1|E9PKG1_HUMAN 686.6  16 51,4 
40 TAB3 sp|Q8N5C8|TAB3_HUMAN 677.4 13 28,4 
41 FLJ53619 tr|B4DGL0|B4DGL0_HUMAN 655.2 15 24,5 
42 HNRNPM sp|P52272|HNRPM_HUMAN 651.9  13 17,7 
43 SPIN tr|A0A024R297|A0A024R297_HUMAN 648.6 12 50,0 
44 RPL7A sp|P62424|RL7A_HUMAN 620.4  12 26,3 
45 HNRNPH1 sp|P31943|HNRH1_HUMAN 610.1 10 33,4 
46 PABPC4 tr|B1ANR0|B1ANR0_HUMAN 594.8  11 19,5 
47 FLJ55253 tr|B4DW52|B4DW52_HUMAN 586.0  11 36,6 
48 TCP1 sp|P17987|TCPA_HUMAN 584.9 16 34,0 
49 HEL-S-97n tr|V9HW63|V9HW63_HUMAN 581.6  11 45,4 
50 N/A tr|A8K4Z4|A8K4Z4_HUMAN 571.8  7 36,0 
51 FLJ55635 tr|B4E0S6|B4E0S6_HUMAN 571.8 17 21,7 
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Table 5. Top 47 proteins identified from Mass spec analysis of Flag IP from 
HEK293T-circZNF609 ORF without doxycycline induction. 
No. 
Protein 
name 
Accession Scores #Peptides 
SC 
[%] 
1 KIF11 sp|P52732|KIF11_HUMAN 4188.7  61 50,9 
2 PPM1B sp|O75688|PPM1B_HUMAN 2820.2  38 65,1 
3 STK38  tr|A0A024RD18|A0A024RD18_HUMAN 2588.9 44 60,4 
4 STK38L sp|Q9Y2H1|ST38L_HUMAN 2455.3 36 52,4 
5 RNF219 sp|Q5W0B1|RN219_HUMAN 2447.5 36 40,1 
6 TUBB tr|Q5SU16|Q5SU16_HUMAN 2258.0  36 65,8 
7 TUBB4B sp|P68371|TBB4B_HUMAN 2189.0  38 68,3 
8 TUBB2A sp|Q13885|TBB2A_HUMAN 1834.8  30 46,1 
9 TUBB2A sp|P04350|TBB4A_HUMAN 1788.2 31 61,7 
10 WDR77  tr|A0A024R0H7|A0A024R0H7_HUMAN 1757.1  27 66,7 
11 C11orf84  sp|Q9BUA3|CK084_HUMAN 1626.6  21 67,7 
12 RIOK1 sp|Q9BRS2|RIOK1_HUMAN 1532.8  29 41,7 
13 HDX sp|Q7Z353|HDX_HUMAN 1472.5 30 48,0 
14 HEL-S-89n tr|V9HWB4|V9HWB4_HUMAN 1428.8 26 39,0 
15 PRMT5 sp|O14744|ANM5_HUMAN 1369.1  26 43,0 
16 KCTD17 sp|Q8N5Z5|KCD17_HUMAN 1326.3 22 52,6 
17 KCTD2 sp|Q14681|KCTD2_HUMAN 1317.5  12 48,7 
18 N/A tr|B3KPS3|B3KPS3_HUMAN 1309.6  21 57,2 
19 TUBA1C sp|Q9BQE3|TBA1C_HUMAN 1249.9 21 54,3 
20 MAP3K7IP1 tr|A8K6K3|A8K6K3_HUMAN 1222.2  23 59,5 
21 EIF4B  sp|P23588|IF4B_HUMAN 1055.4  15 25,4 
22 UNC84B tr|A0A024R1P7|A0A024R1P7_HUMAN 1031.1 21 44,1 
23 OGT sp|O15294|OGT1_HUMAN 1008.6  23 26,1 
24 TUBB6 tr|Q2NKY5|Q2NKY5_HUMAN 999.2 15 26,2 
25 PABPC1 tr|A0A024R9C1|A0A024R9C1_HUMAN 990.1  17 36,3 
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26 N/A tr|Q5U0D0|Q5U0D0_HUMAN 974.5  22 33,0 
27 HSP90AB1 tr|A0A024RD80|A0A024RD80_HUMAN 934.5 20 31,8 
28 N/A tr|A0A140VJQ4|A0A140VJQ4_HUMAN 901.2  18 44,4 
29 EL52 tr|K9JA46|K9JA46_HUMAN 879.6  21 31,3 
30 HNRNPH1 sp|P31943|HNRH1_HUMAN 797.9  14 39,4 
31 KRT5 sp|P13647|K2C5_HUMAN 792.1 17 26,6 
32 CLNS1A sp|P54105|ICLN_HUMAN 786.4 11 56,1 
33 DHX9 sp|Q08211|DHX9_HUMAN 783.1  17 17,2 
34 PRMT1 tr|E9PKG1|E9PKG1_HUMAN 780.3  15 45,8 
35 FLJ51361 tr|B4DWU6|B4DWU6_HUMAN 778.7  14 32,7 
36 RBM10 tr|A0A0S2Z4W4|A0A0S2Z4W4_HUMAN 751.4 18 24,6 
37 DHX15 sp|O43143|DHX15_HUMAN 745.4  18 23,1 
38 TAB3 sp|Q8N5C8|TAB3_HUMAN 729.7 14 23,5 
39 HEL-S-72p  tr|V9HW22|V9HW22_HUMAN 718.8 17 26,6 
40 N/A tr|Q5JPK0|Q5JPK0_HUMAN 717.8 14 26,6 
41 PABPC4  tr|B1ANR0|B1ANR0_HUMAN 690.6 12 25,2 
42 RPS3 sp|P23396|RS3_HUMAN 679.7  16 65,0 
43 SPIN  tr|A0A024R297|A0A024R297_HUMAN 652.6  12 50,0 
44 KCTD5 sp|Q9NXV2|KCTD5_HUMAN 635.6  8 50,9 
45 TRIM21  sp|P19474|RO52_HUMAN 631.5 16 32,6 
46 PRPF31 tr|F1T0A5|F1T0A5_HUMAN 609.6  11 28,3 
47 FLJ35376 tr|B3KS36|B3KS36_HUMAN 594.9  12 25,4 
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6 Materials and methods 
6.1  Materials 
 Instruments 6.1.1
Table 6: The instruments used in this study 
Screen Eraser-K Bio-Rad (Hercules, USA) 
Trans-Blot SD Bio-Rad (Hercules, USA) 
Wet-blot Bio-Rad (Hercules, USA) 
Odyssey Infrared Imaging System LI-COR Biosciences (Lincoln, USA) 
Power Supply EV233 Consort (Turnhout, Belgium) 
Polymax 2040 Heidolph (Schwabach, Germany) 
Vortexer REAX top Heidolph (Schwabach, Germany) 
2720 Thermal Cycler Applied Biosystems (Foster City, USA) 
GeneAmp PCR System 9700 Applied Biosystems (Foster City, USA) 
Mastercycler gradient Eppendorf (Hamburg, Germany) 
Thermomixer compact Eppendorf (Hamburg, Germany) 
Centrifuge 5415D Eppendorf (Hamburg, Germany) 
Hybridization oven T 5042 Heraeus (Hanau, Germany) 
Incubator Model B6200 Heraeus (Hanau, Germany) 
Agilent 2100 Bioanalyzer Agilent Technologies (Böblingen, Germany) 
HeraCell 240i CO2 Incubator Thermo Scientific (Rockford, USA) 
Megafuge 40R Thermo Scientific (Rockford, USA) 
HeraSafe KS Thermo Scientific (Rockford, USA) 
Branson Sonifier 450 Heinemann (Schwäbisch Gmünd, Germany) 
Film Processor CP 1000 AGFA (Mortsel, Belgium) 
Geiger Counter LB123 EG&G Berthold (Bad Wildbad, Germany) 
Microscope Diavert Leica (Wetzlar, Germany) 
Milli-Q PLUS Millipore (Billerica, USA) 
Ultraspec 3300 pro Amersham Biosciences (Little Chalfont, UK) 
Avanti J-20 XP Centrifuge Beckman Coulter (Krefeld, Germany) 
Quantum ST4 PeqLab (Erlangen, Germany) 
FastPrep®24 (with Lysing Matrix D) MP Biomedicals (Santa Ana, USA) 
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  Plasmids 6.1.2
Table 7. Following plasmids were available in advance of this work or purchased 
Name Source Purpose 
VP5-Flag/HA-FA 
(modified pIRES-neo) 
AG Meister Expression of protein N-terminally 
fused to Flag-HA 
pCS2-myc(6)-FAME AG Meister Expression of protein N-terminally 
fused to 6xMyc 
VP5-eYFP AG Meister Control for co-IP 
PCS2-eYFP AG Meister Control for co-IP 
pSuper Empty AG Meister Test expression of shRNA 
targeting circZNF609/circZfp609 
pSuperior Puro AG Meister Test expression of shRNA 
targeting circZNF609/circZfp609 
pSuperior pri-miR-331 GFP AG Meister Test expression of shRNA 
targeting circZNF609/circZfp609 
pLVX Tet One Puro AG Meister Lentiviral plasmids for shRNA 
targeting circZNF609/circZfp609 
TRMPV-Hygro Addgene #27996 Cloning Venus-IRES-HygB for 
lentiviral vectors 
pcDNA3.1 (+)- Zfp609i AG Irene Bozzoni Test expression of circZfp609 
pcDNA3.1 (+)- Zfp609i-3x 
Flag 
AG Irene Bozzoni Test expression of circZfp609 
pcDNA3.1(+) ZKSCAN1 
MCS-WT Split GFP 
Addgene #69908 
 
Overexpression of circZfp609 
pGEM-3E5-T7t 
 
AG So Umekage Production of synthetic 
circZNF609 
pMD2G AG Christoph Klein Production of lentivirus 
pspAX AG Christoph Klein Production of lentivirus 
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 Oligos 6.1.3
Table 8. The oligos used in this study 
No. Name Sequence 
1 VP5-F-ciZNF609 Fw AGTCGGCCGGCCATGTCCTTGAGCAGTGGAG 
2 VP5-A-ciZNF609 Rv GACTGGCGCGCCCTTAGAGTCAACGTCCCAC 
3 q-cirZNF609-Div Fw CAGCGCTCAATCCTTTGGGA 
4 q-cirZNF609-Div Rv GACCTGCCACATTGGTCAGTA 
5 ZNF609 Fw CTGGCTTACCCAAGGAGGTG 
6 ZNF609 Rv GTCAGGTAGTCCGGAGGTCT 
7 m-ciZfp609 F1 GAAGGGGAGAATGAGTGCCG 
8 m-ciZfp609 R1 GTC AAC GTC CCA CCT CAA GGT TC 
9 m-mZfp609 R1 TGA CCA CTG GCA CTA ACA GG 
10 sh-ciZ609 S 01 
GATCTCCAGTCAAGTCTGAAAAGCAATTCAAGAGA
TTGCTTTTCAGACTTGACTTTTTTA 
11 sh-ciZ609 AS 01 
AGCTTAAAAAAGTCAAGTCTGAAAAGCAATCTCTT
GAATTGCTTTTCAGACTTGACTGGA 
12 sh-ciZ609 S 02 
GATCTCCTCTGAAAAGCAATGATGTTTTCAAGAGA
AACATCATTGCTTTTCAGATTTTTA 
13 sh-ciZ609 AS 02 
AGCTTAAAAATCTGAAAAGCAATGATGTTTCTCTTG
AAAACATCATTGCTTTTCAGAGGA 
14 sh-ciZ609 S 03 
GATCTCCGTCAAGTCTGAAAAGCAATTTCAAGAGA
ATTGCTTTTCAGACTTGACTTTTTA 
15 sh-ciZ609 AS 03 
AGCTTAAAAAGTCAAGTCTGAAAAGCAATTCTCTTG
AAATTGCTTTTCAGACTTGACGGA 
16 h-ciZ609-sh01-S NB AGTCAAGTCTGAAAAGCAA 
17 h-ciZ609-sh01-AS NB TTGCTTTTCAGACTTGACT 
18 h-ciZ609-sh02-S NB TCTGAAAAGCAATGATGTT 
19 h-ciZ609-sh02-AS NB AACATCATTGCTTTTCAGA 
20 h-ciZ609-sh03-S NB CCGTCAAGTCTGAAAAGCAAT 
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21 h-ciZ609-sh03-AS NB ATTGCTTTTCAGACTTGACGG 
21 hZNF609 NB 01 
TCAGTACATGCCCAGTGGACAACATCATTGCTTTT
CAGACTTGACTTTCT 
21 m-ciZNF609 NB 
AGAACATGTCCAGTGGACAACATCATTGCTTTTCA
GACTTGACTTTCTTTAGTG 
22 h-ciZ609-sh01-F-QC 
CAAACCCAGTCAAGTCTGAAAAGCAATAACCAACC
TAAGCTCGCGC 
23 h-ciZ609-sh01-R-QC 
ATCTGAAGTCAAGTCTGAAAAGCAATAACAAACCC
AAACAAAAC 
24 h-ciZ609-sh02-F-QC 
CAAACCCCGAGTCTGAAAAGCAATGATAACCAACC
TAAGCTCGCGC 
25 h-ciZ609-sh02-R-QC 
ATCTGTCAAGTCTGAAAAGCAATGATAACAAACCC
AAACAAAAC 
26 h-ciZ609-sh03-F-QC 
CAAACCCAGGTCAAGTCTGAAAAGCAAAACCAACC
TAAGCTCGCGC 
27 h-ciZ609-sh03-R-QC 
ATCTGAAAGTCAAGTCTGAAAAGCAAAACAAACCC
AAACAAAAC 
28 h-ciZ609-sh01 NB AAGTCAAGTCTGAAAAGCAAT 
29 h-ciZ609-sh02 NB TCAAGTCTGAAAAGCAATGAT 
30 h-ciZ609-sh03 NB AAAGTCAAGTCTGAAAAGCAA 
31 pCDNA-ZK-ciZFP Rv 
ACATGTCCAGTGGACAACATCATTGCTGAAGTATA
AAAAAAAAGTCATTAG 
32 pCDNA-ZK-ciZFP Fw 
ACTAAAGAAAGTCAAGTCTGAAAAGGTAAGAAGCA
AGGTTTCATTTAGG 
33 ciZFP-pCDNA-ZK Fw 
TAATGACTTTTTTTTTATACTTCAGCAATGATGTTGT
CCACTGGACATGT 
34 ciZFP-pCDNA-ZK Rv 
CCTAAATGAAACCTTGCTTCTTACCTTTTCAGACTT
GACTTTCTTTAGT 
35 p-ZK-ciZFP-3xF Rv 
CACCGTCATGGTCTTTGTAGTCTTGCTGAAGTATA
AAAAAAAAGTCATTAG 
36 ciZFP-3xF-p-ZK Fw 
CTAATGACTTTTTTTTTATACTTCAGCAAGACTACA
AAGACCATGACGGTG 
43 Flag-pZK Rv TCACTTGTCATCGTCATCCTTGTAATCG 
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44 5UTR-Z609-30del Fw AGGCAGGTCTGAGAACGTAGCTGAAGC 
45 5UTR-Z609-60del Fw AAATAGGAAAGCTGGGGGCAAGGAAGAGC 
46 5UTR-Z609-90del Fw CTTGAACCTTGAGGTGGGACGTTGACTC 
47 5UTR-Z609-121del Fw ATGTCCTTGAGCAGTGGAGCCTGCGGAGGG 
48 Zfp609-A1 QC Fw GACGTTGACTCTAAGCTGTCCTTGAGCAGTG 
49 Zfp609-A1 QC Rv CACTGCTCAAGGACAGCTTAGAGTCAACGTC 
50 Zfp609-A2 QC Fw CAGCAGAAACTGGAACTGTCAGGCTCCAAGG 
51 Zfp609-A2 QC Rv CCTTGGAGCCTGACAGTTCCAGTTTCTGCTG 
52 Zfp609-A1-del QC Fw 
GGGACGTTGACTCTAAGTGTCCTTGAGCAGTGGA
G 
53 Zfp609-A1-del QC Rv CTCCACTGCTCAAGGACACTTAGAGTCAACGTCCC 
54 hRPL32 F AGGCATTGACAACAGGGTTC 
55 hRPL32 R GTTGCACATCAGCAGCACTT 
56 FseI-h-circZNF609 F GATAGGCCGGCCTCCTTGAGCAGTGGAGCCTCCG 
57 AscI-h-circZNF609 R CAGTGGCGCGCCTCATTGCTTTTCAGACTTGACT 
58 ZNF609 420Rv Seq GTCTGGTAGTGTGGCCACAG 
59 ZNF609 310F Seq CCAATGCTGTGGCCACACTA 
60 INTS13 FseI F TCAAGGCCGGCCATGAAGATTTTTTCTGAATCTCA 
61 INTS13 AscI R 
TAGAGGCGCGCCTCACTGCCGGCTGGCTTTTCCA
T 
62 INTS10 FseI F 
TCAAGGCCGGCCATGTCACCTAGCAAACGTAGCT
CT 
63 INTS10 AscI R 
TAGAGGCGCGCCTCAGGTCAGAGTCTGAAGGAGC
A 
64 ZK-Zfp-3ntSS-Del F AGAAGCAAGGTTTCATTTAGGGGAA 
65 ZK-Zfp-3ntSS-Del R CTTTTCAGACTTGACTTTCTTTAGTGG 
66 
5UTR-Z609-121-A del 
Fw 
TGTCCTTGAGCAGTGGAGCCTGCGGAGGG 
67 5UTR-Z609-121-AT del GTCCTTGAGCAGTGGAGCCTGCGGAGGG 
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Fw 
68 
5UTR-Z609-121-ATG 
del Fw 
TCCTTGAGCAGTGGAGCCTGCGGAGGG 
69 pZK-Zfp-1ATG-Flag R 
ATCTTTATAATCACCGTCATGGTCTTTGTAGTCCAT
CTTAGAGTCAACGTCCCACCTC 
70 pZK-Zfp-1ATG-Flag F 
CATGACATCGATTACAAGGATGACGATGACAAGTC
CTTGAGCAGTGGAGCCTGCGGAGG 
71 pGEM-T7t Fw TAATTGAGGCCTGAGTATAAGGTGAC 
72 pGEM-T7t Rv CATTATGTTCAGATAAGGTCGTTAATC 
73 h-ci-Z609-T7t-eFw 
ATCTGAACATAATGCTACCCAATGATGTTGTCCACT
GGGCATGTACTGAC 
74 h-ci-Z609-T7t-e Rv 
GTCACCTTATACTCAGGCCTCAATTAACCCCTTTTC
AGACTTGACTTTCTT 
75 T7t-hZ609-3xFlag-R 
GATCTTTATAATCACCGTCATGGTCTTTGTAGTCTT
GCATTATGTTCAGATAAGGTCG 
76 T7t-hZ609-3xFlag-F 
ATGACATCGATTACAAGGATGACGATGACAAGTGA
TGTTGTCCACTGGGCATGTACTGACC 
77 AflII-Zeo-F 
GATCCTTAAGGCTAGAGCCACCATGGCCAAGTTGA
CCAGTGCCG 
78 BstBI-Zeo-R 
TTCGAACCCCAGAGTCCCGCTCAGTCCTGCTCCTC
GGCCA 
79 pTRE3G-TetOn Fw CGGTAGAATTCTGCTTTGCATACTTCTGCCTG 
80 pTRE3G-TetOn Rv 
TGTCAGCAGATCTACGCGTTTTACGAGGGTAGGAA
GTG 
81 shRNAZ609 Rv 
GTAAAACGCGTAGATCTCCTGCAGGGCTGACAAC
GTACAGAAGGCTCC 
82 shRNAZ609 Fw 
AGCTGGGTACCGTCGACTTAATTAAGATATCGGGC
CCCCCCTCGAGGAAGACTTTG 
83 pS-IRES-Zeo Fw 
ATTCTTCTGACACAACAGTCTCGAAGCCCCTCTCC
CTCCCCCCCCCCTAAC 
84 pS-IRES-Zeo Rv 
CTTGGCCATGGTGGCTCTAGCCTTAAGTGTGGCAA
GCTTATCATCGTGTTTTTC 
85 pLVL-Ven-IRES-HyB f 
GTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTT
GCAAAACGCGACCATG 
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86 pLVL-Ven-IRES-HyB R 
TCCAGAGGTTGATTGTTCCAGACGCGTCTATTCCT
TTGCCCTCGGACGAG 
87 BamHI-sh609-lenti F GTCTGGATCCGGTACCGTCGACTTAATTAAGATA 
88 EcoRI-sh609-lenti R TCGAGAATTCACGCGTAGATCTCCTGCAGGGCTG 
89 pZK-Zfp-1ATG-1xHA R 
GAACATCGTATGGGTACATCTTAGAGTCAACGTCC
CACC 
90 pZK-Zfp-1ATG-1xHA  F 
CTGACTATGCGGGCTCCTTGAGCAGTGGAGCCTG
CGG 
91 pZK-Zfp-2ATG-1xHA  R 
GAACATCGTATGGGTACATTTCCAGTTTCTGCTGG
TCC 
92 pZK-Zfp-2ATG-1xHA  F 
CTGACTATGCGGGCTCAGGCTCCAAGGAGGTGGG
GATAC 
93 3xFlag-ATG-CTG Rv 
ATCTTTATAATCACCGTCGTGGTCTTTGTAGTCTTG
CTGAAGTAT 
94 3xFlag-ATG-CTG Fw 
CACGACATCGATTACAAGGACGACGACGACAAGT
GATGTTGTCCACTGGACATGTTCTGAC 
95 3xFlag-3ATG-CTG Rv 
ATCTTTATAATCACCGTCATGGTCTTTGTAGTCTTG
CTGAAG 
96 AscI-hZNF609 R 
ATATGGCGCGCCTCACCTCCTGGGGGGTGGGTAG
AGT 
97 q-mGapdh Fw CTTCATTGACCTCAACTACATG 
98 q-mGapdh Rv TCGCTCCTGGAAGATGGTGATG 
99 q-hGAPDH Fw TGGTATCGTGGAAGGACTCATGAC 
100 q-hGAPDH Rv ATGCCAGTGAGCTTCCCGTTCAGC 
101 Immature U1 F GATGTGCTGACCCCTGCGATTTC 
102 Immature U1 R GTCTGTTTTTGAAACTCCAGAAAGTC 
103 Immature U2 F TTGCAGTACCTCCAGGAACGG 
104 Immature U2 R CAGGGAAGCAGTTAAGTCAAGCC 
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  Antibodies 6.1.4
Table 9. The antibodies used in this study 
Antibody Properties/Source Dilution 
rat-anti-Ago2  Monoclonal, clone 11A9, Rüdel et al., 2008  1:10 
rabbit-anti-GAPDH Polyclonal, clone, clone FL-335, Santa Cruz 
Biotechnology 
1:500 
mouse-anti-p54nrb 
(NONO) 
Monoclonal, clone 3, BD Biosciences (Franklin 
Lakes, USA) 
1:1000 
mouse-anti-Flag  Monoclonal, clone M2, Sigma Aldrich (Munich, 
Germany) 
1:1000 
mouse-anti-HA Monoclonal, clone 16B12, Covance (Princeton, 
USA)  
1:1000 
rabbit-anti-ZNF609 AV31708, Sigma Aldrich (Munich, Germany) 1:1000  
guinea pig anti-Zfp609 Polyclonal, from Debbie van den Berg et al., 
2017 
1:100 
rabbit-anti-c-Myc  Polyclonal, C3956, Sigma Aldrich (Munich, 
Germany)  
1:1000 
mouse-anti--Tubulin  Monoclonal, clone DM1A, Sigma Aldrich 
(Munich, Germany)  
1:10000 
mouse-anti--Tubulin Abcam (Cambridge, UK)  
rabbit-anti-Lamin A/C  Polyclonal, H-110, Santa Cruz Biotechnology 
(Dallas, USA)  
1:1000 
mouse-anti--Actin  Monoclonal, clone AC15, Abcam (Cambridge, 
UK)  
1:10000 
goat-anti-rabbit 680  secondary antibody, Li-Cor Biosciences (Lincoln, 
USA)  
1:15000 
 
goat-anti-mouse 680  secondary antibody, Li-Cor Biosciences (Lincoln, 
USA)  
1:15000 
goat-anti-rabbit 800  secondary antibody, Li-Cor Biosciences (Lincoln, 
USA)  
1:15000 
goat-anti-mouse 800  secondary antibody, Li-Cor Biosciences (Lincoln, 
USA)  
1:15000 
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goat-anti-rat 800  secondary antibody, Li-Cor Biosciences (Lincoln, 
USA)  
1:15000 
donkey-anti-guinea 
pig 800 
secondary antibody, Li-Cor Biosciences (Lincoln, 
USA) 
1:15000 
goat-anti-rabbit 488  secondary antibody, Life Technologies 
(Carlsbad, USA)  
1:500 
  Bacterial strains 6.1.5
Following Escherichia coli strain was used for cloning: XL1-blue for all plasmids, except 
lentiviral plasmids. Stbl3 was used for all lentiviral plasmids. 
  Mammalian cell lines 6.1.6
All cell lines are listed at ATCC: HEK293T, HCT116, HT29, CMT93. Specifically, 
HCT116.hCG.Luc, HT29.hCG.Luc, CMT93.hCG.Luc cell lines were provided by AG 
Christina Hackl as described previously142,205. 
  Mouse strains 6.1.7
Following mouse strains were used or generated during this study:  
Both C57BL/6 and SCID were obtained from Charles River Laboratories (Sulzfeld) 
 Buffers and solutions 6.1.8
Table 10. List of buffers and solutions used in this study 
Phosphate buffered saline (PBS) 130 mM NaCl 
774 mM Na2HPO4 
226 mM NaH2PO4 
Tris/Borate/EDTA buffer (TBE) 
 
89 mM Tris pH 8,3 
89 mM Boric acid 
2,5 mM EDTA 
Laemmli protein sample buffer 
 
300 mM Tris pH 6,8 
50 % Glycerol 
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10 % SDS 
0,01 % Bromophenol blue 
Tris buffered saline (TBS) 
 
10 mM Tris pH 7,5 
150 mM NaCl 
Proteinase K buffer 
 
300 mM NaCl 
200 mM Tris pH 7,5 
25 mM EDTA 
2 % SDS 
2 x RNA loading dye for Urea PAGE 
 
99,9 % Formamide 
0,05 % Xylene cyanol 
0,05 % Bromphenol blue 
20 x SSC for Northern Blot 
 
3 M NaCl 
0,3 M NaCitrate pH 7,0 
50 x Denhardt’s Solution for  
Northern Blot 
 
1 % Albumin Fraction V 
1 % Polyvinylpyrrolidone K30 
1 % Ficoll 400 
Hybridization solution for  
Northern Blot 
5 x SSC  
20 mM NaPi, pH 7,2  
7 % SDS  
1x Denhardt’s Solution  
EDC crosslinking solution 
 
61,25 ul Methylimidazole 
75 ul 1 M HCl 
188,25 mg EDC 
Ad 6 ml H2O 
Blue Juice 3 mL Glycerol (100%)  
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200 ul 2.5% Bromphenol Blue 
6.8 mL RNase-free H2O 
RNA Loading Buffer (2X) for MOPS 
Agarose  
450 ul Formamide (100%)  
100 ul 10X MOPS  
160 ul Formaldehyde (37%)  
90 ul RNase-free H2O  
200 ul Blue Juice 
Colloidal Coomassie solution 
 
8,3 % H3PO4 
8,3 % (NH4)2SO4 
20 % Methanol 
1 g/L Coomassie Brilliant Blue 
G250 
MOPS-buffer (10X) 200 mM MOPS  
20 mM NaAc  
10 mM EDTA  
Dissolve in RNase-free H20, pH 
7.0  
RNA-Running buffer for  
MOPS Agarose (1X) 
1/10 MOPS buffer (10X)  
2% Formaldehyde (37%)  
Wash Solution 1 for Northern  
Blot (Small RNA) 
5x SSC 
1 % (w/v) SDS 
Wash Solution 2 for Northern  
Blot (Small RNA) 
1x SSC 
1 % (w/v) SDS 
Wash Solution 3 for Northern Blot 
(long and circular RNA) 
2X SSC  
0.1% (w/v) SDS  
Wash Solution 4 for Northern Blot 0.5X SSC  
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(long and circular RNA) 
 
0.1% (w/v) SDS  
Wash Solution 5 for Northern Blot 
(long and circular RNA) 
0.1X SSC  
0.1% (w/v) SDS 
SDS running buffer 
 
200 mM Glycine 
25 mM Tris pH 7,5 
25 mM SDS 
Towbin buffer 
 
38,6 mM Glycine 
48 mM Tris 
0,0037 % (w/v) SDS 
20 % Methanol 
IP lysis buffer 150 mM KCl 
25 mM Tris pH 7,5 
2 mM EDTA 
1 mM NaF 
0,5 % NP-40 
1mM DTT 
1mM AEBSF 
IP wash buffer 
 
300 mM NaCl 
50 mM Tris pH 7,5 
1 mM NaF 
0,01 % NP-40 
5 mM MgCl2 
2 x HEPES for Calcium phosphate 
transfection 
 
274 mM NaCl 
54,6 mM Hepes 
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1,5 mM Na2HPO4 
PBS-A for IF 
 
0,2 g KCl 
0,2 g KH2PO4 
8 g NaCl 
2,2 g Na2HPO4 _ H2O 
ad. 1 l H2O, adjust to pH 7,4 
Fixation solution for IF 
 
4 % paraformaldehyde (PFA) in 
PBS-A 
Stopping solution for IF 100 mM Glycine in PBS-A 
Permeabilization solution for IF 
 
0,1 % Triton-X-100 in PBS-A 
Wash solution for IF 
 
5 % bovine serum albumin (BSA) 
0,01 % Triton-X-100 
ad PBS-A 
Hypotonic lysis buffer (HLB) 10 mM Tris (pH 7.5) 
10 mM NaCl 
3 mM MgCl2 
0.3% (vol/vol) NP-40  
10% (vol/vol) glycerol 
  
Nuclear lysis buffer (NLB) 20 mM Tris (pH 7.5) 
150 mM KCl 
3 mM MgCl2 
0.3% (vol/vol) NP-40 
10% (vol/vol) glycerol 
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6.2  Methods 
 Methods for working with DNA 6.2.1
 General molecular cloning 6.2.1.1
General methods like DNA gel electrophoresis, PCR, purification, and extraction of DNA 
were performed according to Sambrook et al., 1989 or as described according to 
manufacturer’s manuals. Cloning was performed using T4 DNA ligase (Thermo Scientific) 
or with T4 DNA polymerase (Thermo Scientific) according to SLIC methods206.  
For plasmids DNA isolation from E.coli, the NucleoSpin Plasmid (Macherey-Nagel, Düren, 
Germany) or NucleoBond XtraMidi-Kit (Macherey-Nagel, Düren, Germany) was used. For 
the elution of DNA fragments from agarose gels, the NucleoSpin Gel and PCR-cleanup 
(Macherey-Nagel, Düren, Germany) was used. 
Sequencing has been done at Macrogen (Amsterdam, Netherlands). DNA concentration 
and quality were determined using NanoDrop 1000 Spectrophotometer (Thermo Scientific, 
Rockford, USA). 
 List of plasmids cloned during this study 6.2.1.2
Table 11. Details about plasmids cloned during this study 
Name Source/plasmid 
backbone 
Cloning 
oligos 
Cloning 
enzyme 
Shorted name 
used in the 
figures 
VP5-Flag/HA-FA-
circZNF609 ORF 
VP5-Flag/HA-FA 56, 57 FseI/AscI VP5-
circZNF609 
ORF 
VP5-Flag/HA-FA-
circZfp609 ORF 
VP5-Flag/HA-FA 1, 2 FseI/AscI VP5-
circZfp609 
ORF 
VP5-Flag/HA-FA-
ZNF609 
VP5-Flag/HA-FA 96, 56 FseI/AscI VP5-ZNF609 
ORF 
pCS2-myc(6)-
INTS10 
pCS2-myc(6x) 60, 61 FseI/AscI 6xMyc INTS10 
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pCS2-myc(6)-
INTS13 
pCS2-myc(6x) 62, 63 FseI/AscI 6xMyc INTS13 
pSuper sh 
ZNF609 01 
pSuper 10, 11 BglII, 
HindIII 
 
pSuper sh 
ZNF609 02 
pSuper 12, 13 BglII, 
HindIII 
 
pSuper sh 
ZNF609 02 
pSuper 14, 15 BglII, 
HindIII 
 
pSuperior CMV-sh 
ZNF609 01 
pSuperior pri-
miR-331 
22, 23 Quick 
change 
 
pSuperior CMV-sh 
ZNF609 02 
pSuperior pri-
miR-331 
24, 25 Quick 
change 
 
pSuperior CMV-sh 
ZNF609 03 
pSuperior pri-
miR-331 
26, 26 Quick 
change 
 
pSuperior CMV-
pri-miR-331 GFP- 
Zeocin 
pSuperior CMV-
pri-miR-331 GFP 
77, 78 AfllI, 
BstBI 
 
pSuperior TRE-pri-
miR-331 GFP- 
Zeocin 
pSuperior CMV-
pri-miR-331 GFP- 
Zeocin 
79, 80 EcoRI, 
BglII 
 
pSuperior TRE-sh 
ZNF609 01 GFP- 
Zeocin 
pSuperior TRE-
pri-miR-331 GFP- 
Zeocin 
81, 82 KpnI, 
MluI 
 
pSuperior TRE-pri- 
sh ZNF609 01 
GFP-IRES-Zeocin 
pSuperior TRE-
sh ZNF609 01 
GFP- Zeocin 
83, 84 AflII & 
SLIC 
 
pLVX Tet One 
Venus-IRES-HygB 
pLVX Tet One 
Puro 
85, 86 AvrII, 
MluI & 
SLIC 
 
pLVX Tet One -sh 
ZNF609 01 
Venus-IRES-HygB 
pLVX Tet One 
Venus-IRES-
HygB 
87, 88 BamHI, 
EcoRI 
 
pcDNA3.1(+) pcDNA3.1(+) 31, 32, SLIC ZK-circZfp609 
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ZKSCAN1 
circZfp609 
ZKSCAN1 MCS-
WT Split GFP 
33, 34 
pcDNA3.1(+) 
ZKSCAN1 
circZfp609- 3xFlag 
pcDNA3.1(+) 
ZKSCAN1 MCS-
WT Split GFP 
32, 34, 
35, 36 
SLIC ZK-circZfp609-
3xFlag 
pcDNA3.1(+) 
ZKSCAN1 
circZfp609- 3xFlag 
1st AUG -> CUG 
pcDNA3.1(+) 
ZKSCAN1 
circZfp609- 
3xFlag 
48, 49 Quick 
change 
1st AUG -> 
CUG 
pcDNA3.1(+) 
ZKSCAN1 
circZfp609- 3xFlag 
2nd AUG -> CUG 
pcDNA3.1(+) 
ZKSCAN1 
circZfp609- 
3xFlag 
50, 51 Quick 
change 
2nd AUG -> 
CUG 
pcDNA3.1(+) 
ZKSCAN1 
circZfp609- 3xFlag 
1st AUG -> UG  
pcDNA3.1(+) 
ZKSCAN1 
circZfp609- 
3xFlag 
52, 53 Quick 
change 
1st AUG -> UG 
pcDNA3.1(+) 
ZKSCAN1 
circZfp609 delSS 
pcDNA3.1(+) 
ZKSCAN1 
circZfp609- 
3xFlag 
64, 65 Quick 
change 
ZK-circZfp609-
delSS 
pcDNA3.1(+) 
ZKSCAN1 
circZfp609- 3xFlag 
del SS 
pcDNA3.1(+) 
ZKSCAN1 
circZfp609- 
3xFlag 
64, 65 Quick 
change 
ZK-circZfp609-
3xFlag-delSS 
pcDNA3.1(+) 
ZKSCAN1 
circZfp609- 3xFlag 
del 30 
pcDNA3.1(+) 
ZKSCAN1 
circZfp609- 
3xFlag 
43, 44 Quick 
change 
Del 30 
pcDNA3.1(+) 
ZKSCAN1 
circZfp609- 3xFlag 
del 60 
pcDNA3.1(+) 
ZKSCAN1 
circZfp609- 
3xFlag 
43, 45 Quick 
change 
Del 60 
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pcDNA3.1(+) 
ZKSCAN1 
circZfp609- 3xFlag 
del 89 
pcDNA3.1(+) 
ZKSCAN1 
circZfp609- 
3xFlag 
43, 46 Quick 
change 
Del 89 
pcDNA3.1(+) 
ZKSCAN1 
circZfp609- 3xFlag 
del 121 
pcDNA3.1(+) 
ZKSCAN1 
circZfp609- 
3xFlag 
43, 47 Quick 
change 
Del 121 
pcDNA3.1(+) 
ZKSCAN1 
circZfp609- 3xFlag 
del 121-A 
pcDNA3.1(+) 
ZKSCAN1 
circZfp609- 
3xFlag 
43, 66 Quick 
change 
Del 121-A 
pcDNA3.1(+) 
ZKSCAN1 
circZfp609- 3xFlag 
del 121-AU 
pcDNA3.1(+) 
ZKSCAN1 
circZfp609- 
3xFlag 
43, 67 Quick 
change 
Del 121-AU 
pcDNA3.1(+) 
ZKSCAN1 
circZfp609- 3xFlag 
del 121-AUG 
pcDNA3.1(+) 
ZKSCAN1 
circZfp609- 
3xFlag 
43, 68 Quick 
change 
Del 121-AUG 
pcDNA3.1(+) 
ZKSCAN1 
circZfp609- 3xFlag 
4 AUG -> CUG 
pcDNA3.1(+) 
ZKSCAN1 
circZfp609- 
3xFlag 
93, 94 Quick 
change 
 
pcDNA3.1(+) 
ZKSCAN1 
circZfp609- 3xFlag 
3 last AUG -> 
CUG 
pcDNA3.1(+) 
ZKSCAN1 
circZfp609- 
3xFlag 
94, 95 Quick 
change 
 
pcDNA3.1(+) 
ZKSCAN1 
circZfp609- 3xFlag 
1st AUG-1xHA 
pcDNA3.1(+) 
ZKSCAN1 
circZfp609- 
3xFlag 
89, 90 Quick 
change 
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pcDNA3.1(+) 
ZKSCAN1 
circZfp609- 3xFlag 
2nd AUG-1xHA 
pcDNA3.1(+) 
ZKSCAN1 
circZfp609- 
3xFlag 
91, 92 Quick 
change 
 
pcDNA3.1(+) 
ZKSCAN1 
circZfp609- 3xFlag 
first AUG 
pcDNA3.1(+) 
ZKSCAN1 
circZfp609 
69, 70 Quick 
change 
ZK-circZfp609-
3xFlag first 
AUG 
pGEM-3E5-T7t-
apdel 
pGEM-3E5-T7t 
 
71, 72 Quick 
change 
pGEM-3E5-
T7t-apdel 
pGEM-3E5-T7t-
circZNF609 
pGEM-3E5-T7t 71, 72, 
73, 74 
Quick 
change 
circZNF609 
pGEM-3E5-T7t-
circZNF609 
3x Flag 
pGEM-3E5-T7t- 
circZNF609 
 
75, 76 Quick 
change 
circZNF609 
3x Flag 
 Methods for working with RNA 6.2.2
 RNA isolation 6.2.2.1
RNA extraction from mammalian cells has been done with TRIzol reagent (Life 
Technologies, Carlsbad, USA) or NucleoSpin RNA Kit (Macherey-Nagel, Düren, Germany) 
following the manufacturer’s protocol.  
To isolate RNA from tissues, the mouse tissue was mechanically disrupted using 
FastPrep-24 (MP Biomedicals) with lysing matrix D containing 1ml TRIzol reagent. The 
program is set for 45 s at 6.5 m/s. Afterwards, the ceramic beads in TRIzol were incubated 
at RT for 5 mins and then following the TRIzol manual. 
RNA extraction from the blood, serum, cell lysates or in vitro transcription was collected in 
750 ul TRIzol-LS reagent (Life Technologies, Carlsbad, USA) following TRIzol-LS manual. 
RNA isolation from MOPS-Agarose gel was performed using Zymoclean™ Gel RNA 
Recovery Kit (Zymo Research) following the manufacturer’s protocol.  
After isolation, RNA was resuspended and stored in H2O at -80
oC. 
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 RNA concentration and quality control 6.2.2.2
RNA concentration was determined using NanoDrop 1000 Spectrophotometer (Thermo 
Scientific, Rockford, USA). For Urea PAGE, RNA quality for Northern Blot was additionally 
checked by nucleic acid staining of gels in TBE supplemented with 5 µl/100ml EtBr. For 
MOPS Agarose, RNA was stained with 2,3 µl EtBr (400µg/ml) each sample before loading 
into Agarose gel.  RNA for deep sequencing RNAseq was analyzed using Bioanalyzer 
2100 (Agilent Technologies, Santa Clara, USA). 
 Urea PAGE 6.2.2.3
RNA polyacrylamide gel electrophoresis was performed using the UreaGel System 
(National Diagnostics). Different components were mixed according to the chosen 
percentage and the manufacturer’s protocol and gels were polymerized for at least 1 h. 
Afterwards, the gels were pre-run at 250-400 V for about 15-30 min using 1x TBE buffer. 
Samples were heated at 95oC for 2-3 min and loaded into the freshly rinsed wells. 
Electrophoresis was performed in 1x TBE buffer at a voltage between 250-400 V until the 
desired requirements.  
 MOPS Agarose 6.2.2.4
The gel was prepared with the appropriate amount of agarose (1%) in water. After melting 
and cooling down to 65oC, 1x MOPS buffer and 2% Formaldehyde (37%) were added. 
After pouring and polymerizing, the gel was pre-run for 15-30 minutes at 70V in 1x MOPS 
buffer. 10 µl of 2x RNA loading dye was added to 10 µl of 20 µg of RNA samples. After 
incubating at 65oC for 10 minutes, samples were chilled on ice. 2.3 µl of EtBr (400 µg/ µl) 
were added directly into the samples before loading into the gel. For size quantification of 
sizes, the RNA ladder RiboRuler High Range RNA Ladder (Thermo Scientific) was used. 
The gel was run at 70 V until the dye approximately 1 cm above the end of the gel. 
 Semi-Dry Blotting for Urea PAGE 6.2.2.5
In order to transfer the RNA from the Urea PAGE gel onto the nitrocellulose membrane 
(Amersham Hybond-N), 8 Whatman Paper with the exact measurements of the gel was 
prepared as well as a nitrocellulose membrane. 4 pieces of Whatman Paper were soaked 
in Milli-Q H2O and placed onto semi-dry blot as well as the membrane, the gel and the rest 
of the Whatman paper, followed by the removal of any bubbles. The blotting took place for 
30-60 minutes at constant 20 V. 
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For crosslinking of RNA to the membrane, the EDC crosslinking solution was prepared. 
This solution was added to a Whatman Paper with the exact size of the membrane. The 
membrane was placed on top of this saturated Whatman Paper with the RNA side up, 
wrapped and placed into a hybridization oven at 50oC for 1 hour. Afterwards, the 
membrane was washed 3 times with Milli-Q H2O to remove excess crosslinking solution 
for 20 s each wash. 
 Capillarity transferring for MOPS Agarose gel 6.2.2.6
Once the gel was checked under UV light, it was soaked and shaked into Milli-Q water for 
5 minutes followed by 50mM NaOH for 30 minutes, 50mM Tris pH 7.5 for 30 minutes and 
20xSSC for 30 minutes at room temperature. Afterwards, the transfer was set up by 
disposing a glass plate on top two square dishes filled with 20xSSC. Two strips of 
Whatman paper were soaked into 2xSSC and laid on a plate in order to hang both ends 
into the 20xSSC of the dishes. After removing bubbles, the gel was placed facedown. The 
area around the gel was sealed with parafilm to prevent 20XSSC from ‘short-circuiting’. 
The nitrocellulose membrane (Amersham Hybond-N) of the size of the gel was soaked into 
Milli-Q water and 2xSSC and it was placed on the gel. After removing all bubbles, three 
2xSSC-soaked pieces of Whatman paper were placed on the membrane. A stack of towel 
papers was put on top with a second glass plate and an additional weight of 500 g. The 
transfer was set at room temperature overnight, preferably for 18 hours, after which the 
success of transfer was verified by visualizing the membrane under UV light. The RNA 
was crosslinked to the membrane using the UV Stratalinker at 254 nm. 
  Prehybridization of the membrane 6.2.2.7
For prehybridization of the membrane, 20-30 ml Hybridization Solution was put into a 
cylindrical glass bottle, in which the membrane was already put into with the RNA facing 
inwards, and then placed in a hybridization oven at 42-60oC for 60 minutes. 
 Preparation of probes 6.2.2.8
The DNA probes were used for the detection of small RNAs, overexpressed RNAs or 
abundant long RNAs. There are single-stranded DNA oligonucleotides, about 50 nts. 
Probe labeling was done using 20 pmol DNA oligonucleotide with 20 µCi of γ 32P-ATP 
(Hartmann Analytics, Braunschweig, Germany) using T4 PNK enzyme (Life Technologies, 
Carlsbad, USA) according to the manufacturer’s protocol. The reaction was incubated for 
60 min at 37oC. The reaction was mixed with 30 µl 30 mM EDTA to stop PNK reaction. 
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The cDNA probes were prepared using Megaprime DNA-Labeling Systems kit 
(Amersham). Afterward, the reaction was stopped with 5 µl 200 mM EDTA.  
The DNA or cDNA probes were purified using Illustra MicroSpin G-25 columns (GE 
Healthcare, Little Chalfont, UK) and flow through are collected. The DNA probes are 
directly added to the prehybridized membranes. The cDNA probes are denatured by 
heating them to 95oC for 5 minutes and then immediately placed on ice. Then, the cDNA 
probes were added to the prehybridized membranes.  
 Northern blot wash and detection 6.2.2.9
The membrane labeled with DNA probes was washed twice with Northern Blot wash 
solution 1 and once with Northern Blot wash solution 2, incubating each wash step for 10 
mins on a turning wheel at the same temperature as prehybridization and hybridization.  
The membrane labeled with cDNA probes was washed once with Northern Blot wash 
solution 3, once with Northern Blot wash solution 4 and once with Northern Blot wash 
solution 5, incubating each wash step for 30 mins on a turning wheel at the same 
temperature as prehybridization and hybridization. 
After the last step, the liquid was discarded and the membrane was wrapped in saran for 
exposure to a phosphor screen and then signals were scanned by Personal Molecular 
Imager System (Bio-Rad, Hercules, USA).  
 Stripping of Northern blot membranes 6.2.2.10
In order to reuse the membrane, the membranes were stripped off the current probe. 
Water was boiled, then an SDS solution was carefully added to reach a final concentration 
of 0.1% SDS. The membrane was rolled up with the RNA facing inwards. Repeat this step 
2 times. After a final wash with only boiled water, the membrane was wrapped in saran 
and exposed to a screen for at least over night to control the removal of the probe. 
 First strand cDNA synthesis  6.2.2.11
For qPCR, RNA was preferably isolated using NucleoSpin RNA Kit (Macherey-Nagel, 
Düren, Germany) including DNA digestion step. 1 µg RNA was used for cDNA synthesis 
using First Strand cDNA Synthesis Kit (Thermo Scientific, Rockford, USA) according to its 
manual. 
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 Quantitative real-time PCR (qPCR) 6.2.2.12
qPCR was done with Sso Fast Eva Green Mix (Bio-Rad, Hercules, USA) using 0,5 µM 
forward and 0,5 µM reverse primer and cDNA from 10 ng RNA as template. qPCR was run 
on a CFX96 cycler (Bio-Rad, Hercules, USA) using the standard program as given in the 
SsoFast EvaGreen SuperMix manual. Data were evaluated using the ∆∆Ct method with 
GAPDH or RPL32 as reference mRNA and normalized to control sample.  
 RNA in vitro transcription using T7 polymerase 6.2.2.13
The reaction requires a DNA template containing the T7 promoter upstream of the 
sequence and the corresponding T7 RNA polymerase (homemade from AG Meister). In 
order to perform the in vitro transcription, 2 µg of DNA templates was prepared with 1x T7 
buffer, 5 mM NTPs, 5mM MgCl2, TIPP, Ribolock (Thermo Scientific) and 25 µl of T7 
polymerase (2 µg/µl) in DEPC-treated water in a final volume of 500 µl. The in vitro 
transcription was performed at 37oC for 3 hours. For increasing of self-splicing reaction of 
circRNA, the reaction was shifted to 55oC for 30 mins. Afterwards, the reaction was 
digested with 1 µl of 1U/unit DNase I (Thermo Scientific) for 15 mins at 37oC. 
The RNA reaction was then purified using TRIzol-LS reagents.  
 RNA treatment with RNase R 6.2.2.14
RNA was treated with RNase R (Biozym) according to manufacturer’s protocol. The 
reaction was cleaned up using NucleoSpin RNA Kit (Macherey-Nagel, Düren, Germany). 
 Poly-(A) (+/-) isolation from total RNA 6.2.2.15
mRNA was isolated using Dynabeads™ Oligo(dT)25 (Thermo Scientific) according to 
manufacturer’s protocol. The flow-through was collected and served as poly A (–) RNA. 
The RNA after isolation was collected and cleaned up from the magnetic beads using 
NucleoSpin RNA Kit (Macherey-Nagel, Düren, Germany). 
 Methods for working with proteins 6.2.3
 Preparation of whole cell extracts from mammalian cells 6.2.3.1
Cell extracts were prepared using IP lysis buffer. About 4 million cells were thoroughly 
resuspended in 100 µl IP lysis buffer by pipetting and incubated on ice for 20 min. Lysates 
were then cleared by centrifugation at full speed for 15 min at 4oC. The supernatant was 
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supplemented with Laemmli buffer or LDS buffer (for NuPAGE® 4- 12% Bis-Tris Gel) or 
used for IP.  
 Preparation of whole cell extracts from tissues 6.2.3.2
The mouse tissue was mechanically disrupted using FastPrep®-24 (MP Biomedicals) with 
lysing matrix D containing 200-600 l IP lysis buffer. The program is set for 45 s at 6.5 m/s. 
Afterward, the lysate was collected and was cleared at full speed for 15 min at 4oC. The 
supernatant was collected and supplemented with Laemmli buffer. 
 Preparation of subcellular extracts. 6.2.3.3
Nucleo-cytoplasmic fractionations were prepared according to Nature Protocols as 
described in Gagnon et al. 2014 with slight modifications. HEK293T cells were cultured up 
to 80 % confluency, washed with PBS and harvested by trypsin. The cells were then 
passed through a cell strainer and washed again with ice-cold PBS. After centrifugation at 
100 g for 5 min at 4oC, the cell pellet was resuspended by gentle pipetting with ice-cold 
hypotonic lysis buffer (HLB) and incubated for 8 min on ice. 1ml of HLB was used for every 
75 mg cell pellet (or 10 million cells). Afterwards, cells were centrifuged at 800g for 8 mins 
at 4oC.  The supernatant of this step served as cytoplasmic fraction. The nuclei pellet was 
washed gently for 4 times with HLB through pipetting and centrifugation at 200 g for 2 mins 
at 4oC. Nuclei were resuspended nuclear lysis buffer (NLB). 0,5 ml of NLB was used for 
every 75mg of initial cells used (or 10 million cells). If needed, the nuclear pellet was 
sonicated on ice one time with 10-20 % power for 15s. Both fractions were cleared by 
centrifuge at 15.000 g for 15 mins at 4oC. 
 Determination of protein concentrations 6.2.3.4
For the determination of protein concentrations in solutions containing a mixture of several 
different proteins (e.g. cellular lysates), a Bradford Protein Assay (Biorad) was used and 
performed according to the protocol of the distributor and as described in (Bradford, 1976) 
  Immunoprecipitation (IP) 6.2.3.5
Anti-FLAG M2 agarose beads (Sigma-Aldrich) was used for IP of FLAG/HA-tagged 
proteins that were overexpressed in HEK293T cells. Prior to use, the matrix was washed 
with cold PBS twice. First of all, after preparing the total cell lysates, input samples were 
collected, supplemented with LDS sample buffer, heated at 70oC for 15 mins and stored at 
−20oC. For immunoprecipitation, the lysate was incubated with the antibody-coupled 
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beads for at 2-3 h while rotating at 4oC. After incubation, the beads were sedimented by 
centrifugation for 1 min at 1,000 g and the supernatant was removed. The beads were 
washed with the IP wash buffer four times. During the last washing step, the samples were 
transferred to new reaction tubes to minimize contamination by unspecific protein binding 
to the tube material. After a final washing step with PBS, the supernatant was removed 
quantitatively and the beads were eluted with Flag peptides.  
 SDS-PAGE and Western blotting 6.2.3.6
NuPAGE® 4-12% Bis-Tris Gel (Invitrogen, Life Technologies) was used for samples 
prepared for Mass Spec. The proteins were visualized with Coomassie.  
For performing a Western blot, samples were shortly heated at 95oC for 5 mins and then 
loaded onto a 10-15% SDS-PAGE gel. After separation, the proteins were blotted onto an 
Amersham Hybond-ECL membrane (GE Healthcare) using Towbin buffer for 1 min/kDa 
constant at 1 mA/cm2. The membrane was blocked in TBS containing 0.1% Tween20 and 
5% milk powder and subsequently incubated with the primary antibody overnight at 4°C. 
After three washing steps with TBS containing 0.1% Tween 20, the secondary antibody 
was added for 1 hour at RT. After three washing steps with TBS containing 0.1% Tween 
20, the membrane was scanned on a LI-COR reader. 
 Mass-spectrometric analyses  6.2.3.7
After gradient-gels or SDS gels were destained, bands or gel parts were excised and 
transferred into 2ml micro tubes (Eppendorf), washed for 30 min with 500 µl 50 mM 
NH4HCO3, 50 mM NH4HCO3/ acetonitrile (3/1), 10 mM NH4HCO3/ acetonitrile (3/1), 10 mM 
NH4HCO3/ acetonitrile (1/1) and lyophilized. After reduction and alkylation of cysteines with 
100 µl 1mg/ml DTT (57oC/ 35 min) and 200 µl 5 mg/ml Iodoacetamide (RT/ 35 min) solved 
in 50 mM NH4HCO3, gel slices were washed again and lyophilized. Proteins were 
subjected to in-gel tryptic digest overnight at 37oC with 0,8 μg Trypsin Gold mass 
spectrometry grade (Promega) per sample. Peptides were first extracted twice with 100 
mM NH4HCO3, followed by 100 mM NH4HCO3/ acetonitrile (2/1) and eluates were 
combined and lyophilized. Further processing was executed by Dr. Astrid Bruckmann or 
Eduard Hochmuth.  
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 Methods for working with cells 6.2.4
 Working with bacterial cells 6.2.4.1
For transformations, chemically competent E. coli XL1-blue was used for all plasmids 
except lentiviral plasmids. For lentiviral vectors, Stbl3 was used. Briefly, appropriate 
amounts of plasmids or ligation or SLIC products were used for transformations. After 
adding the plasmids to the bacterial cells, the cells were incubated on ice for at least 15 
min and subjected to a 60 s heat shock at 42oC. After 2 mins incubation on ice, 1 ml of LB 
medium without antibiotic was added, and the cells were incubated at 37oC for at least 20 
min while shaking. Appropriate amounts of LB containing bacteria were plated on LB 
plates containing suitable antibiotic. LB plates for XL1-Blue were incubated overnight at 
37oC. LB plates for Stbl3 were incubated overnight at 30-32oC. 
The colonies are picked and incubated overnight in LB medium containing suitable 
antibiotics at the desired temperature.  
 Working with mammalian cells  6.2.4.2
All cell lines were cultivated at 37oC in a humidified chamber with air atmosphere and 
addition of 5 % CO2 on uncoated plastic surface. All cell lines were cultured with DMEM 
media supplemented with 10% FCS, 1% PS. 
6.2.4.2.1 Cell transfection with calcium phosphate 
Only HEK 293T cells were transfected using calcium phosphate. Per 15 cm plate, 10 µg 
DNA and 123 µl of 2 M CaCl2 were filled up to 1 ml with water in a reaction tube. 
Afterwards, 1 ml of 2x HEPES were added dropwise into the DNA-containing solution. The 
mixture was incubated for 10 minutes at room temperature and then added to the cells. 
The cells were harvested after 24-28 hours. Per 10 cm plate, half of the reagents were 
used. 
6.2.4.2.2 Cell transfection with Lipofectamine 2000 Reagent 
2ml of 400.000 cells/ml were seeded into 6-wells plates. 500 ng of in vitro transcribed RNA 
was added to 250 µl of Opti-MEM. In a second tube, 10 µl of Lipofectamine 2000 was 
added into 250 µl of Opti-MEM. The mixture was incubated at RT for 5 mins. After 
incubation, both tubes were mixed together and incubated at room temperature for further 
15 minutes. 500 µl of the mixture was added drop-by-drop to the cells. 4 hours post-
transfection, the medium was removed and replaced with 2ml of fresh DMEM with 10% 
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FBS and 1% PS. The cells were incubated for 16 hours. RNA was harvested 4 hours and 
16 hours post-transfection. 
For the transfection of plasmids, the same procedure was applied as with in vitro 
transcribed RNA and in this case, 2,5 µg of plasmids were used. For transfection in other 
culture disk format, the reagents are scaled according to manufacturer’s 
recommendations. 
6.2.4.2.3 Cell transfection with Lipofectamine RNAiMAX 
For siRNA, the transfection was performed as described for Lipofectamine 2000 Reagent 
with some modification. For example, the same amount of cells and Opti-MEM were used 
in 6-wells plates. In this scale, 10 µl of Lipofectamine RNAiMAX was used and a desired 
amount of siRNA was used (instead of 500 ng in vitro transcribed RNA as above). The 
cells were harvested after 72-96 hours.   
6.2.4.2.4 Generation of stable cell lines via Lipofectamine 2000 transfection  
For generation of stable HEK293T, HCT116.hCG.Luc or CMT93.hCG.Luc cell line 
expressing desired constructs, the cells were transfected with plasmids in 6-well format. 
Cells were split one day post-transfection into one 10 cm plate and selection was started 
with 100 µg/ml Zeocin. The cells are shorted for GFP-expressing cells using FACS Aria 
system (BD Biosciences, Franklin Lakes, USA). Stable clones were maintained in the 
same medium as used for selection. 
6.2.4.2.5 Generation of stable cell lines via lentiviral transduction 
Lentivirus was generated at the S2 lab (AG Christoph Klein).  Briefly, the HEK293T cells 
were propagated in DMEM media supplemented with 10% FCS, 1% PS and L-glutamine. 
6 x 106 cells were seeded in a 10 cm cell culture dishes 16h before transfection. 
Transfection medium (DMEM; 10% FCS) containing 25 μM chloroquine was added 45 min 
before the start of transfection. Afterward, chloroquine was replaced by transfection 
mixture. 
5 μg pMD2G (envelope plasmid), 20 μg psPAX2 (packaging plasmid), 20 μg lentiviral 
plasmid were used for preparation of the mix for calcium phosphate transfection. The 
transfection mixture was added dropwise to HEK293T cells. The medium was replaced 6 
hours post-transfection. The viral particles were collected 48h and 72h post-transfection, 
filtered, concentrated and stored at -80oC for at least 6 months. 
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The HT29.hCG.Luc, HCT116.hCG.Luc, CMT93.hCG.Luc cells (4 x 104 cells/well) were 
plated and propagated in 6 well-plates overnight at 37oC. On the next day, after changing 
to the new medium virus dilution of 1:10, 1:100, 1:1000, 1:10000 was added to the cells. 
After 24 hours, 100 µg/ml Hygromycin B was added for lentiviral transduction cell lines. 
The cells were selected in Hygromycin B for 3 passages. Afterward, all the cell lines can 
be moved to the S1 lab. The cells are shorted for GFP-expressing cells using FACS Aria 
system (BD Biosciences, Franklin Lakes, USA). Stable clones were maintained in the 
same medium as used for selection. 
6.2.4.2.6 Proliferation assay  
Single cell suspensions were obtained after trypsinization and passing through a cell 
strainer. XXT were performed in 96 well plates using XTT colorimetric assay kit (Roche) 
based on manufacturers instruction. Specifically, 300 cells/well for HT29.hCG.Luc or 
HCT116.hCG.Luc cell lines or 100 cells/well for CMT93.hCG.Luc cell lines were seeded in 
12 replications. 6 hours after seeding, 6 replications were replaced with DMEM media 
supplemented with 10% FCS, 1% PS while the other 6 replications were replaced with 
DMEM media supplemented with 10% FCS, 1% PS, 1 µg/ml Doxycycline. The XTT are 
assayed every day for 6-8 days. Statistics analysis was performed using GraphPad Prism. 
6.2.4.2.7 Preparation for cell sorting  
Cells were dissociated with trypsin, washed once in DMEM supplemented with 10% FCS, 
1% PS. Single cells were obtained by passing through a cell strainer and then 
resuspended to the desired concentration, preferably 20 million cells/ml, in PBS.  
6.2.4.2.8 Immunofluorescence 
The cells were seeded in 24-well plates with 12 mm diameter cover slips of thickness #1,5 
(0,15-0,19 mm) for confocal microscopy (Carl Roth, Karlsruhe, Germany). The stable cell 
lines HT29.hCG.Luc or HCT116.hCG.Luc expressing shRNA targeting circZNF609 were 
treated with 1µg/ml Doxycycline for at least 4 days before staining. For overexpression, the 
cells are fixed 2 days post-transfection.  
PBS, fixation solution and stopping solution were prewarmed to 37oC before addition to 
cells to prevent damage to cell morphology prior to fixation. All steps were done in 24-well 
format with 500 µl volumes for all washing steps or 300 µl for antibody-containing 
134                                                                                          MATERIALS AND METHODS 
 
 
 
solutions. Cells were washed once with PBS, fixed with fixation solution for 10 mins at 
37oC and stopped with stopping solution for 5 mins.  
Then, the cells were washed once with PBS and permeabilized with permeabilization 
solution for 30 mins at room temperature. After washing off detergent once with PBS, cells 
were blocked with blocking solution containing 5 % BSA for 1 hour at room temperature. 
Primary antibody was incubated in blocking solution for 1 h at room temperature or 
overnight at 4oC. After three washing steps with blocking solution and incubation for 5 min 
at RT between each step, the secondary antibody was added and incubated for 1 h at 
room temperature. Cells were then washed once with blocking solution and trice with PBS 
and incubated for 2 min between each wash. Afterward, PBS is removed by water.  
Coverslips were then mounted using 8 µl Prolong Gold with DAPI (Life Technologies, 
Carlsbad, USA) and dried for minimum 12 h. 
Confocal microscopy has been done with a TCS SP8 (Leica Microsystems, Mannheim, 
Germany) inverted microscope equipped with an acousto-optical beam splitter, 405 nm 
laser (for DAPI), Argon laser (488 nm for Alexa 488 and GFP) and DPSS laser 561 nm (for 
Alexa 555). 
 Methods for working with animals 6.2.5
 Cell preparation for injection 6.2.5.1
Cells were dissociated with trypsin, washed once in DMEM supplemented with 10% FCS, 
1% PS. Single cells were obtained by passing through a cell strainer and then 
resuspended to the desired concentration in Hank's Balanced Salt Solution (HBSS). All 
animals receiving tumor cell injections were injected with the same quantity of tumor cells 
(0,5 million cells per animal) 
 Tumor implantation 6.2.5.2
All experimental procedures were conducted in accordance with German laws governing 
animal care. All tumor implantation was performed by Dr. Christina Hackl with the 
assistance from a technician Marvin Anders.  
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 Subcutaneous implantation 6.2.5.3
50 µl of 0,5 million tumor cells were injected subcutaneously into C57BL/6  mice using a 
manual 1 ml Hamilton syringe and 30G needle (BD Biosciences). Tumor size was 
measured daily (normally 5 days after implantation) with calipers and tumor volume 
calculated as width x width x length as described142.  
 Intrasplenic implantation 6.2.5.4
Intrasplenic implantation was performed with SCID mice. Abdominal access was obtained 
via a left subcostal skin and peritoneal wall incision. The spleen was gently exteriorized. 5 
µl of 0,5 million tumor cells were injected with a 10 µl Hamilton syringe (BD Biosciences). 
The needle was slowly retracted and the injection site pressed with a moist cotton swab to 
prevent leakage. The spleen was returned to the peritoneal cavity; peritoneum and skin 
were closed by running sutures and wound clips. 
 Bioluminescence measurement  6.2.5.5
Bioluminescence measurement was performed weekly or every 3 days. For this purpose, 
mice were anaesthetized, injected with 100 µl of 30 mg/ml D-luciferin (Biosynth, Staad, 
Switzerland) for 3 minutes, and emitted photons were registered for 3 min using Xenogen 
IVIS Lumina Imaging System (Caliper Life Sciences, Hopkinton, USA). 
 Doxycycline treatment 6.2.5.6
Doxycycline was obtained from Sigma Aldrich (Munich, Germany). The mice were 
gavaged daily with 100 µl of 5 mg/ml Doxycycline as described207. 
 Tumor resections 6.2.5.7
Primary tumor (either subcutaneous tumor or at spleen) and metastases in the liver 
resections were performed when then tumor size is big enough or when the 
bioluminescence measurement is significant. Samples of primary tumors and liver 
metastasis were weighted, imaged with a normal camera. All the tumors are divided into 
different parts for RNA, protein or immunohistochemistry analysis. Statistics analysis was 
performed using GraphPad Prism 
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 Next generation sequencing and data analysis 6.2.6
 Generation of small RNA libraries 6.2.6.1
Isolated RNA was ligated to an adenylated 3’ adapter by a truncated T4 RNA Ligase 2 
(expressed and purified from AG Meister), the 5’ RNA adapter was added in a second 
ligation step by T4 RNA Ligase 1 (NEB). The product was reverse-transcribed using the 
SuperScriptIII First Strand Synthesis Super Mix (Invitrogen) using a specific primer, 
followed by a PCR amplification. The samples were run on a 6% Urea-PAGE, the bands 
corresponding to small RNA containing ligation products were cut out and eluted overnight 
in elution buffer (300 mM NaCl, 2 mM EDTA). The libraries were precipitated with ethanol 
overnight at -20°C, then collected by centrifugation and solved in water. The library was 
sequenced on a MiSeq (Illumina) in a 1x66 bp run.  
 Analysis of small RNA data 6.2.6.2
Data analysis was performed using in-house written scripts. Sequences were mapped, 
without any mismatches allowed, against human miRNAs listed in the miRBase v20 (June 
2013; http://www.mirbase.org). The minimum length of reads was set to 18 nucleotides. 
Annotated miRNA reads were normalized as RPM values according to the total number of 
mapped reads in the respective library. 
 Generation of rRNA-depleted RNA libraries 6.2.6.3
The rRNA-depleted RNA library was prepared using Ovation Human FFPE RNA-Seq 
Libray System according to manufacturer’s protocol. Specifically, 100 ng of total RNA from 
frozen samples was used.  
 Bioinformatics analysis of circRNAs 6.2.6.4
Bioinformatics analysis of circRNAs was performed by Petar Glazar from the Rajewsky 
lab. Specifically, circRNAs were detected and annotated as described before26. Genome 
references used for all mapping and subsequent analyses were human hg19 (Feb 2009, 
GRCh37). Quantification of circRNAs expression from sequencing data was performed as 
described65.   
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